<SEC-DOCUMENT>0001193125-24-268106.txt : 20241129
<SEC-HEADER>0001193125-24-268106.hdr.sgml : 20241129
<ACCEPTANCE-DATETIME>20241129161906
ACCESSION NUMBER:		0001193125-24-268106
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20241129
DATE AS OF CHANGE:		20241129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyell Immunopharma, Inc.
		CENTRAL INDEX KEY:			0001806952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				833006753
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283533
		FILM NUMBER:		241516560

	BUSINESS ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650 695-0677

	MAIL ADDRESS:	
		STREET 1:		201 HASKINS WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d907660ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on November&nbsp;29, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Lyell Immunopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1300510</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>201 Haskins Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">695-0677</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Lynn Seely, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Lyell Immunopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>201 Haskins Way </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>South
San Francisco, California 94080 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">695-0677</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Thomas Greenberg </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>One Manhattan West </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10001 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">735-3000</FONT> </B></P>
<P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: From time to time after the effective date of this Registration
Statement. </P> <P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans,
please check the following box:&#8194;&#9744; </P> <P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&#8194;&#9744; </P>
<P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this
Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&#8194;&#9744; </P> <P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;&#9744; </P>
<P STYLE="margin-top:7pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. The
selling stockholders may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these
securities and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED NOVEMBER 29, 2024 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g907660g03k03.jpg" ALT="LOGO" STYLE="width:1.625in;height:1.20833in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>37,499,981 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
relates to the proposed resale from time to time by the selling stockholders identified in this prospectus of up to 37,499,981 shares of our common stock, par value $0.0001 per share. The shares of common stock registered for resale pursuant to this
prospectus were issued as part of the merger consideration under an Agreement and Plan of Merger, dated as of October&nbsp;24, 2024 (the &#147;Merger Agreement&#148;), by and among ImmPACT Bio USA Inc., a Delaware corporation (&#147;ImmPACT
Bio&#148;), us, Inspire Merger Sub Inc., a Delaware corporation and our indirect, wholly owned subsidiary (&#147;Merger Sub&#148;), and WT Representative LLC, a Delaware limited liability company, solely in its capacity as the representative of the
Company Securityholders (as defined in the Merger Agreement) (the &#147;Representative&#148;), pursuant to which we acquired ImmPACT Bio through the merger of Merger Sub with and into ImmPACT Bio (the &#147;Merger&#148;), with ImmPACT Bio surviving
the Merger as the surviving entity and our indirect, wholly owned subsidiary. The Merger Agreement provides for the issuance by Lyell of 37,500,000 shares of our common stock to the selling stockholders, provided that in the event any fractional
shares of our common stock are owed to any selling stockholder, in lieu of such issuance, such fractional shares are to be paid in cash. After accounting for the cash payments we made to certain selling stockholders in lieu of fractional shares, we
issued a total of 37,499,981 shares of our common stock to the selling stockholders in connection with the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the
shares of our common stock on behalf of the selling stockholders, to be offered and sold by them from time to time. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the
selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the common stock the selling stockholders may offer. The selling
stockholders may sell the shares of our common stock described in this prospectus in a number of different ways and at varying prices. See the section titled &#147;<I>Plan of Distribution for Shares Offered by Selling Stockholders&#148;</I> on page
15 of this prospectus for more information about how the selling stockholders may sell the shares of common stock being registered pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay the expenses incurred in registering the shares of common stock, including certain legal and accounting fees. The
selling stockholders will bear all underwriting discounts, selling commissions and similar fees and arrangements and stock transfer taxes allocable to their respective sales of the shares of our common stock and certain additional legal and advisor
fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#147;LYEL.&#148; On November&nbsp;27, 2024,
the last reported sale price of our common stock was $0.92 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should review carefully the
risks and uncertainties described under the section titled &#147;<A HREF="#tx907660_3">Risk Factors</A>&#148; contained in this prospectus and under similar headings in the documents that are incorporated by reference into this
prospectus.</I></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is&#8195;&#8195;&#8195;&#8195;, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_7">SELLING STOCKHOLDERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_8">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_9">PLAN OF DISTRIBUTION FOR SHARES OFFERED BY SELLING STOCKHOLDERS</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx907660_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;), utilizing a &#147;shelf&#148; registration process under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Under this shelf registration process, the selling stockholders, which as
used herein include donees, pledgees, transferees, distributees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of our common stock or interests in our common stock
received after the date of this prospectus from the selling stockholders as a gift, pledge, partnership distribution or other transfer identified in this prospectus, may offer and sell up to 37,499,981 shares of our common stock. This prospectus
provides a general description of the shares of our common stock the selling stockholders may offer. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling
stockholders. For general information about the distribution of shares of common stock offered by the selling stockholders, see the section in this prospectus titled &#147;<I>Plan of Distribution for Shares Offered by Selling Stockholders</I>&#148;.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the
sections titled &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation of Certain Information by Reference</I>&#148;, before buying any of the shares of our common stock being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus. We have not authorized any other
person to provide you with different or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We take no responsibility for, and can provide no assurance as to the reliability of, any
other information that others may give you. You should assume that the information appearing in this prospectus and the documents incorporated by reference into this prospectus, is accurate only as of the date of those respective documents. Our
business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus and the documents incorporated by reference into this prospectus, in their entirety before making an investment
decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus titled &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation of Certain
Information by Reference</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock
only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of our securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this
prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in
connection with, an offer to sell, or a solicitation of an offer to buy, any shares of common stock offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtained the industry and market data included or incorporated by reference in this prospectus from our own research as well as from
industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions
and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this
prospectus titled &#147;<I>Risk Factors</I>&#148; and documents incorporated by reference into this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the information incorporated by reference into this prospectus, includes trademarks, service marks and
trade names owned by us or others. All trademarks, service marks and trade names included or incorporated by reference in this prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contain summaries of
certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the
documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described in the sections
titled &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation of Certain Information by Reference</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere in this prospectus or incorporated by reference in this prospectus and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read this entire prospectus, including the risks of investing in our securities discussed under the section titled &#147;Risk
Factors&#148; and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial
statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context requires
otherwise, references in this prospectus to &#147;Lyell,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Lyell Immunopharma, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage cell
therapy company advancing a pipeline of proprietary next-generation chimeric antigen receptor (&#147;CAR&#148;) <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidates for patients with solid tumors or hematologic malignancies. We have
developed novel technologies and manufacturing protocols designed to generate T cells that resist exhaustion and have qualities of durable stemness to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses. Our
investigational therapies use the patient&#146;s own living cells as the starting point. We incorporate our innovative technology and manufacturing protocols to expand and activate the patient&#146;s T cells. Our technologies are designed to
generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to persist, self-renew and kill cancer cells over time. Our technology can be applied in a target agnostic manner to multiple T-cell modalities, including CAR,
tumor-infiltrating lymphocytes and T-cell receptor therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline of next-generation CAR
<FONT STYLE="white-space:nowrap">T-cell</FONT> product candidates target indications with large unmet need and provide opportunities to expand into additional indications beyond the patient populations we are initially evaluating. Our lead product
candidates are summarized in Table 1 below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g907660g08k08.jpg" ALT="LOGO" STYLE="width:6.30557in;height:3.16187in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in June 2018. Our primary activities to date have included clinical development of <FONT
STYLE="white-space:nowrap">T-cell</FONT> therapies, conducting research and development, acquiring technology and product candidates, entering into strategic collaboration and license agreements, enabling and executing manufacturing activities in
support of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our product candidate development efforts, organizing and staffing our company, business planning, establishing our intellectual property portfolio, making regulatory submissions, executing
clinical trials, raising capital and providing general and administrative support for these activities. We are early in our research and development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently acquired ImmPACT Bio, a privately-owned clinical stage biotechnology company developing next-generation CAR <FONT
STYLE="white-space:nowrap">T-cell</FONT> product candidates including a dual-targeting CD19/CD20 CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate currently in Phase 1 clinical development for the treatment of aggressive <FONT
STYLE="white-space:nowrap">B-cell</FONT> <FONT STYLE="white-space:nowrap">non-Hodgkin</FONT> lymphoma. In conjunction with this acquisition, we prioritized our pipeline to focus resources on our most differentiated next generation CAR <FONT
STYLE="white-space:nowrap">T-cell</FONT> product candidates, including <FONT STYLE="white-space:nowrap">IMPT-314</FONT> for patients with aggressive <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma and LYL119. LYL119, our next-generation <FONT
STYLE="white-space:nowrap">ROR1-targeted</FONT> CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate, has received FDA clearance of its Investigational New Drug (&#147;IND&#148;) application and is entering a Phase 1 dose-escalation,
dose-expansion clinical trial, initially in patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer. We do not have any products approved for sale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in June 2018 as a Delaware corporation. Our principal executive offices are located at 201 Haskins Way, South San Francisco, California 94080 and our telephone number is (650) <FONT STYLE="white-space:nowrap">695-0677.</FONT> Our
website address is www.lyell.com. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it as part of this prospectus. Our website address is included in
this prospectus as an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lyell logo and other trademarks or service marks of Lyell Immunopharma, Inc.
appearing in this prospectus are the property of Lyell. Other trademarks, service marks or trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies&#146; trade
names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>The Securities the Selling Stockholders May Offer </B></P></TD>
<TD>The selling stockholders may offer up to 37,499,981 shares of our common stock, from time to time in one or more offerings under this prospectus, at prices and on terms to be determined by market conditions at the time of any offering. This
prospectus provides you with a general description of the common stock the selling stockholders may offer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The selling stockholders may sell shares of our common stock directly to investors or to or through agents, underwriters or dealers. The selling stockholders and their agents or underwriters reserve the right to accept
or reject all or part of any proposed purchase of shares our common stock. If the selling stockholders do offer shares of our common stock to or through agents or underwriters, a prospectus supplement, if required, will be distributed, which will
include, among other things: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those agents or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid; and details regarding options to purchase additional
shares, if any. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may suspend the sale of our shares of common stock by the selling stockholders pursuant to this prospectus for certain periods of time for certain reasons, including if the prospectus is required to be supplemented
or amended to include additional material information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any then-outstanding shares of
preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, the holders of our common stock
are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then-outstanding shares of preferred stock. Holders of our common stock have no preemptive rights and no right to convert their
common stock into any other securities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights
of the holders of shares of any series of preferred stock that we may designate in the future. In this prospectus, we have summarized certain general features of our common stock under the section titled &#147;<I>Description of Capital Stock &#151;
Common Stock</I>&#148;. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P></TD>
<TD>We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares of our common stock by the selling stockholders. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P></TD>
<TD>Our common stock is listed on the Nasdaq Global Select Market<B></B>&nbsp;under the symbol &#147;LYEL.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P></TD>
<TD>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risks and uncertainties discussed under the section titled &#147;Risk Factors&#148; in this
prospectus and our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by our subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in
subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus and the other documents incorporated by reference into this prospectus.
</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider
the risks and uncertainties discussed under the section titled &#147;<I>Risk Factors</I>&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by our subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus
and the other documents incorporated by reference into this prospectus. The risks described in these documents are not the only ones we face. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors
that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of
these risks actually occur, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our securities to decline, resulting in a loss of all or a part of your investment.
Please also read carefully the section below titled &#147;<I>Special Note Regarding Forward-Looking Statements</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, as well as the documents incorporated by reference in this prospectus, contain &#147;forward-looking statements&#148; within
the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). These statements relate to our future events, including our anticipated operations,
research, development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or
achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy and timing of our estimates regarding expenses, revenue opportunities, capital requirements and
needs for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of developing <FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or
any other product candidates we may acquire or develop, and conducting nonclinical studies and clinical trials, including for <FONT STYLE="white-space:nowrap">IMPT-314</FONT> and LYL119; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs involved in obtaining and maintaining regulatory approvals of
<FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop, and the timing or likelihood of regulatory filings and approvals, including any expectations or plans regarding seeking special
designations, such as Regenerative Medicine Advanced Therapy designation or Fast Track designation, for our product candidates for various diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the commercialization of <FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any
other product candidates we may acquire or develop, if approved, including the geographic areas of focus, and our ability to commercially differentiate such product candidates and grow a sales force; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the market opportunities for <FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other
product candidates we may acquire or develop in each of the diseases we may target; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct research activities for
<FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the characteristics, safety, efficacy and therapeutic effects of
<FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the advancement of our technology platform and the effectiveness and expected benefits of any of our technologies
and manufacturing processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the number of patients in the United States and worldwide who suffer from the diseases we target
and the number of patients that may enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and focus of the current and planned clinical trials of our product candidates, and the reporting of
data from those trials, including the timing thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to sufficiently demonstrate the safety and efficacy of <FONT
STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop, and other clinical trial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are, or may become, available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including any existing or future competing product
candidates or therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of
<FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop, including additional indications that we may pursue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential and ability to successfully manufacture and supply or our ability to contract with third parties to
manufacture and supply <FONT STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop for clinical trials and for commercial use, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance, as well as the pricing and reimbursement, of <FONT
STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to assist us in conducting additional clinical trials of <FONT
STYLE="white-space:nowrap">IMPT-314,</FONT> LYL119 or any other product candidates we may acquire or develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights, including
covering our product candidates and technology platforms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional
qualified personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of inflation, macroeconomic conditions and geopolitical conflicts on our
business and operations, including on our manufacturing suppliers, collaborators, contract research organizations and employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to realize the anticipated benefits of and potential value created by our acquisition of ImmPACT Bio
or any other acquisition or strategic transaction and our success in commercializing any product candidates we acquire in connection therewith, including <FONT STYLE="white-space:nowrap">IMPT-314;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inherent risks, costs and uncertainties associated with integrating the businesses in the merger with ImmPACT
Bio successfully and the amount of any costs, fees, expenses, impairments and charges relating to the merger with ImmPACT Bio; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing cash, cash equivalents and marketable securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of
operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by use of future dates or by terms such
as: &#147;anticipates,&#148; &#147;believes,&#148; &#147;continues,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;should,&#148;
&#147;will,&#148; &#147;likely,&#148; &#147;ongoing,&#148; &#147;project,&#148; &#147;assume,&#148; &#147;target,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;objective,&#148; &#147;aim,&#148; &#147;goal&#148; and similar expressions
intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these assumptions, risks and uncertainties, you
should not place undue reliance on these forward-looking statements. We cannot guarantee that any forward-looking statement will be realized. We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of
these risks and uncertainties under the section titled &#147;<I>Risk Factors</I>&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by our subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the
applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means
that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus together with the documents we have filed with the SEC that are incorporated by reference into this prospectus completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the shares of our common stock to be sold pursuant to this prospectus will be sold by the selling stockholders. We will not receive any of
the proceeds from the sale of shares of our common stock by the selling stockholders pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay
the expenses incurred in registering the shares of our common stock, including certain legal and accounting fees. The selling stockholders will bear all underwriting discounts, selling commissions and similar fees and arrangements and stock transfer
taxes allocable to their respective sales of the shares of our common stock and certain additional legal and advisor fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, pursuant to our amended and restated certificate of corporation (the &#147;Restated Certificate&#148;), our
authorized capital stock consists of 500,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. All of our authorized shares of preferred stock are undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This information may not be complete in all respects and is qualified entirely by reference to the provisions of the Restated Certificate, our
amended and restated bylaws (&#147;Bylaws&#148;), our amended and restated investors&#146; rights agreement with certain investors and purchasers, dated as of March&nbsp;5, 2020 (the &#147;Investors&#146; Rights Agreement&#148;), our Registration
Rights Agreement with the Representative and certain former stockholders of ImmPACT Bio, dated as of October&nbsp;31, 2024 (the &#147;Registration Rights Agreement&#148;) and the General Corporation Law of the State of Delaware. For information on
how to obtain copies of the Restated Certificate, our Bylaws, our Investors&#146; Rights Agreement and our Registration Rights Agreement, which are exhibits to the registration statement of which this prospectus forms a part, see the section in this
prospectus titled &#147;<I>Where You Can Find More Information</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights. </I>Our common stock is entitled to one vote per share on any matter that is submitted to a vote of our stockholders. Our
Restated Certificate does not provide for cumulative voting for the election of directors. Our Restated Certificate establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only the directors in
one class will be subject to election by a plurality of the votes cast at each annual meeting of our stockholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of
holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our Restated Certificate, including provisions relating to amending our
Bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and
exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Economic Rights. </I>Except as otherwise expressly provided in our Restated Certificate or required by
applicable law, all shares of common stock will have the same rights and privileges and rank equally, share ratably and be identical in all respects for all matters, including those described below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dividends. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the
holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may
determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Liquidation Rights. On our liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the
holders of common stock will be entitled to share equally, identically and ratably in all assets remaining after the payment of any liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any
outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of such affected class, voting separately as a class. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>No Preemptive or Similar Rights. </I>The holders of our shares of common stock are not entitled to preemptive rights, and are not subject
to conversion, redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable.</FONT></I> When
shares of common stock are issued under this prospectus, the shares will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Restated
Certificate, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or
restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deterring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights. </I>The Delaware General Corporation Law provides that the holders of preferred stock will have the right to vote separately
as a class on any proposal involving fundamental changes in the rights of holders of that preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Economic Rights. </I>Unless we specify otherwise, the preferred stock will rank, with respect to dividends and upon our liquidation,
dissolution or winding up: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all of our equity securities the terms of which specifically provide that the equity securities
rank on a parity with the preferred stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all of our equity securities the terms of which specifically provide that the equity securities rank
senior to the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable.</FONT></I> When we issue shares of preferred stock, such shares will
be fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to federal securities laws, certain holders of shares of our common stock are entitled to certain rights with respect to registration
of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of our Investors&#146; Rights Agreement and our
Registration Rights Agreement, as described in additional detail below. The registration of shares of our common stock pursuant to the exercise of such registration rights would enable the holders to trade these shares without restriction under the
Securities Act when an applicable registration statement is declared effective by the SEC. We will pay the registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered in connection
with the exercise of such demand rights and piggyback rights, and associated Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statements, as applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investors&#146; Rights Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain
holders of our common stock are entitled to certain demand registration rights at any time after 180 days after June&nbsp;16, 2021, the effective date of the registration statement for our initial public offering. The holders of 40% of these shares
may request that we register all or a portion of their shares. We are not required to file more than two registration statements which are declared or ordered effective by the SEC. Such request for registration must cover shares with an anticipated
aggregate offering price of at least $35&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, certain holders of shares of our common stock were entitled to, and the
necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain holders of shares of common stock will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration
statement registration rights. Holders of 20% of these shares can make a request that we register their shares on a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement if we are qualified to file such registration statement and
if the reasonably anticipated aggregate net proceeds of the shares offered would equal or exceed $20&nbsp;million. We will not be required to file more than two Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statements within any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing underwriter, if any, has the
right, subject to specified conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement registration rights will expire no later
than five years after our initial public offering in June 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger, on October&nbsp;31, 2024 (the &#147;Closing&#148;), we entered into the Registration Rights
Agreement, pursuant to which we agreed to provide former ImmPACT Bio stockholders certain registration rights in connection with the shares of our common stock, including to file shelf registration statements to permit resale of closing stock
consideration and equity milestone consideration issuable under the Merger Agreement. The closing stock consideration has been issued in connection with the Closing, and the equity milestone consideration that may be issued consists of 12,500,000
shares of our common stock that may be earned upon the achievement of the earlier to occur of (i)&nbsp;the demonstration of certain clinical milestones or (ii)&nbsp;the receipt of certain regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, upon request by the demanding stockholders to sell any registrable shares of our common stock held by such demanding
stockholders in an underwritten offering pursuant to any of the shelf registration statements, we are obligated to effect such an underwritten shelf takedown if the total offering price exceeds $25&nbsp;million. The Representative, on behalf of the
demanding stockholders, is not entitled to request such underwritten shelf takedown (i)&nbsp;more than three times in the aggregate or (ii)&nbsp;more than one time in any single calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, each selling stockholder may not sell more than ten percent (10%) of the average daily trading volume of our common stock over the
five (5)&nbsp;business day period ending on the business day immediately prior to the date of the proposed sale, other than pursuant to a block trade or other disposition through a market participant designated by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware law, our Restated Certificate and our Bylaws, which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage
persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages
of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restated Certificate
and Bylaws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our
shares of common stock are able to elect all of our directors. Our Restated Certificate and our Bylaws provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. According to our Bylaws, a special meeting of stockholders may only be called by a
majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our Bylaws require an advance notice procedure for stockholder proposals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors. In addition, our board of directors is divided into three classes with staggered three-year terms. Our Restated Certificate also provides that directors
may be removed only for cause by the affirmative vote of the holders of at least 66 2/3% of the shares then entitled to vote at an annual election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a
vacancy resulting from an increase in the size of our board, may be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing provisions will make it more difficult for another party to obtain control of us by replacing our board of directors. Since our
board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated
preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be
used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a
consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;203 of the Delaware General Corporation Law </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law (Section 203). In general, Section&nbsp;203
prohibits a publicly-held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, subject to certain
exceptions. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested stockholder&#148; is a person who,
together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate
provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state
court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the
following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative claim or cause of action brought on our behalf; (ii)&nbsp;any claim or cause of action for a breach of fiduciary duty owed by any of our current
or former directors, officers or other employees to us or our stockholders; (iii)&nbsp;any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the
Delaware General Corporation Law, our Restated Certificate or our Bylaws (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our Restated Certificate or our
Bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of
Delaware; and (vi)&nbsp;any claim or cause of action against us or any of our current or former directors, officers or other employees governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the
court&#146;s having personal jurisdiction over the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indispensable parties named as defendants. Our Restated Certificate further provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted
by law, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against a defendant to
such complaint. The choice of forum provisions would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, these provisions are intended to benefit and may be enforced by us, our officers and directors, the underwriters
to any offering giving rise to such complaint and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. While
the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance
that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our Restated Certificate provides that any person or entity holding, owning or otherwise acquiring any interest in any of our
securities shall be deemed to have notice of and consented to these provisions. These choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our
directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, but will not waive our compliance with federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by
Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate authorizes us to indemnify our directors, officers,
employees and other agents to the fullest extent permitted by Delaware law. Each of our Restated Certificate and Bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware
law and may indemnify our other employees and agents. Our Bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of
any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to
continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including,
among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and
retain qualified persons as directors and officers. We also maintain directors&#146; and officers&#146; liability insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our Restated Certificate and
Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action,
if successful, might benefit us and our stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent&#146;s address is 55 Challenger Road, 2nd floor, Ridgefield Park, NJ&nbsp;07660. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 under the
Securities Act (&#147;Rule 144&#148;), a person who has beneficially owned our restricted common stock for at least six months would be entitled to sell their shares of our common stock provided that (i)&nbsp;such person is not deemed to have been
our affiliate at the time of, or at any time during the three months preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports
under Section&nbsp;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as required to file such reports) preceding the sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned our restricted common stock for at least six months but who are our affiliates at the time of, or at any
time during the three months preceding, a sale would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares of our common stock that does not exceed the greater of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of shares of our common stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of our common stock during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by our affiliates under Rule 144 are also limited by
manner of sale provisions and notice requirements and by the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Global Select
Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;LYEL.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have prepared this prospectus to allow the selling stockholders, which as used herein includes donees, pledgees, transferees, distributees
or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of our common stock or interests in our common stock received after the date of this prospectus from the selling
stockholders as a gift, pledge, partnership distribution or other transfer, to offer and sell from time to time up to 37,499,981 shares of our common stock. We are registering the offer and sale of the shares beneficially owned by the selling
stockholders to satisfy certain registration obligations that we granted the selling stockholders in connection with the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following tables set forth, based upon information currently known by us as of the date of this prospectus, (i)&nbsp;the name of each selling stockholder, (ii)&nbsp;the aggregate number of shares of common stock beneficially owned by each selling
stockholder, (iii)&nbsp;the aggregate number of shares of common stock that the selling stockholders may offer pursuant to this prospectus and (iv)&nbsp;the number of shares of common stock beneficially owned by each selling stockholder assuming all
of the shares covered hereby are sold. We have based percentage ownership of securities beneficially owned prior to this offering on 292,161,656 shares of our common stock outstanding as of November&nbsp;26, 2024. We do not know how long the selling
stockholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any shares, except that, pursuant to the Registration
Rights Agreement, each selling stockholder may not sell more than ten (10%) of the average daily trading volume of our common stock over the five (5)&nbsp;business day period ending on the business day immediately prior to the date of the proposed
sale, other than pursuant to a block trade or other disposition through a market participant designated by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined
beneficial ownership in accordance with the rules and regulations of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on
information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in the footnotes in the tables below, to our knowledge, none of the selling stockholders have held any position or office,
or otherwise had a material relationship, with us or any of our subsidiaries within the past three years prior to the date of this prospectus other than as a result of the ownership of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section in this prospectus titled &#147;<I>Plan of Distribution for Shares Offered by Selling Stockholders</I>&#148; for further
information regarding the selling stockholders&#146; methods of distributing these securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the
selling stockholders will in fact sell any or all of our shares of common stock. A selling stockholder may sell or otherwise transfer all, some or none of such shares of our common stock in this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;Beneficially&nbsp;Owned</B><br><B>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;to&nbsp;be&nbsp;Sold</B><br><B>in&nbsp;this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;Beneficially&nbsp;Owned</B><br><B>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Selling&nbsp;Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of</B><br><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Arkin Bio Capital LP<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Bukwang Pharmaceutical Co., Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,410,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,410,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">CFAM 2017 LLC<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,745,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,745,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Decheng Capital Global Life Sciences Fund IV,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,909,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,795,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,114,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Excellent Capital LLC<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foresite Capital Fund V, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,133,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,225,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,907,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;Beneficially&nbsp;Owned</B><br><B>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;to&nbsp;be&nbsp;Sold</B><br><B>in&nbsp;this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities&nbsp;Beneficially&nbsp;Owned</B><br><B>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Selling&nbsp;Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of</B><br><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foresite Capital Opportunity Fund V,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,020,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,569,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,451,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Handok Inc.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Hayan I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc.<SUP
STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">823,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">823,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">JVC CPF LLC<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Novartis Bioventures Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,241,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,241,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">OrbiMed Israel Partners II, LP<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,103,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,103,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">RMGP <FONT STYLE="white-space:nowrap">Bio-Pharma</FONT> Investment Fund L.P.<SUP
STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,633,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,633,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Takeda Ventures, Inc.<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">823,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">823,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Torrey Coast Ventures, LLC<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">venBio Global Strategic Fund IV,
LP<SUP STYLE="font-size:75%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,102,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,102,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Y&amp;S International Co.,Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Moshe Arkin, as the Director of Arkin Bio Ventures GP GP Ltd, the General Partner of Arkin Bio Capital General
Partner Limited Partnership, which is the General Partner of Arkin Bio Capital LP, has voting, investment and dispositive power over the shares held by Arkin Bio Capital LP. The address of Arkin Bio Capital LP is Hamenofim 11 Herzliya, Building B,
Israel. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bukwang Pharmaceutical Co., Ltd. is an affiliate of OCI Holdings Company Ltd., a publicly traded company. As a
major shareholder, OCI Holdings Company Ltd. may be deemed to have beneficial ownership over the shares held by Bukwang Pharmaceutical Co., Ltd. The address of Bukwang Pharmaceutical Co., Ltd. is 7, <FONT STYLE="white-space:nowrap">Sangdo-ro,</FONT>
<FONT STYLE="white-space:nowrap">Dongjak-gu,</FONT> Seoul, Republic of Korea. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neil L. Cohen, as the Special Member of CFAM 2017 LLC has voting, investment and dispositive power over the
shares held by CFAM 2017 LLC. The address of CFAM 2017 LLC is 909 Third Avenue, 15th Fl, New York, NY 10022, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,745,001 shares of our common stock held by Citadel Multi-Strategy Equities Master Fund Ltd.
(&#147;CEMF&#148;). Citadel Advisors LLC (&#147;Citadel Advisors&#148;) is the Portfolio Manager of CEMF. Citadel Advisors Holdings LP (&#147;CAH&#148;) is the Sole Member of Citadel Advisors. Citadel GP LLC (&#147;CGP&#148;) is the General Partner
of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the
disposition of, the shares held by CEMF. This response is not and shall not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related entities listed above is the beneficial owner of any securities of the Company other than
the securities actually owned by such person (if any). The address of CEMF is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The column titled &#147;Shares of Common Stock&#148; under &#147;Securities Beneficially Owned Prior to
Offering&#148; consists of (i) 5,795,032 shares of common stock received as consideration in connection with the Merger and (ii) 6,114,309 shares of common stock purchased on the Nasdaq Global Select Market prior to and after the Merger. Xiangmin
Cui, as the Manager of the Sole General Partner of Decheng Capital Global Life Sciences Fund IV, L.P., has voting, investment and dispositive power over the shares held by Decheng Capital Global Life Sciences Fund IV, L.P. Prior to the
Company&#146;s acquisition of ImmPACT, Xiangmin Cui, while a Managing Director at Decheng Capital Global Life Sciences Fund IV, L.P., was an ImmPACT Board Member and Nomination Governance Committee Member for the period of January 2022 through
October 2024. The address of Decheng Capital Global Life Sciences Fund IV, L.P. is 3000 Sand Hill Road, <FONT STYLE="white-space:nowrap">#2-110,</FONT> Menlo Park, CA 94025, United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Simon S Zhang, as the Manager of Excellent Capital LLC, has voting, investment and dispositive power over the
shares held by Excellent Capital LLC. The address of Excellent Capital LLC is 18575 Jamboree Road, Suite 330, Irvine, CA 92612, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The column titled &#147;Shares of Common Stock&#148; under &#147;Securities Beneficially Owned Prior to
Offering&#148; consists of (i) 4,225,547 shares of common stock received as consideration in connection with the Merger and (ii) 3,907,500 shares of common stock purchased on the Nasdaq Global Select Market prior to the Merger, held with J.P. Morgan
Securities LLC, each held directly by Foresite Capital Fund V, L.P. (&#147;Fund V&#148;). Foresite Capital Management V, LLC (&#147;FCM V&#148;) is the General Partner of Fund V and may be deemed to have sole voting and dispositive power of the
shares held by Fund V. James Tananbaum is the Sole Managing Member of FCM V and may be deemed to have sole voting and dispositive power over the shares held by Fund V. Each of FCM V and Dr.&nbsp;Tananbaum disclaims beneficial ownership of such
shares except to the extent of their respective pecuniary interests therein. Prior to the Company&#146;s acquisition of ImmPACT, Cindy Xiong, a Partner at Foresite Capital Management, LLC, was an ImmPACT Director from January&nbsp;14, 2022 through
October&nbsp;31, 2024. The business address of Dr.&nbsp;Tananbaum, Fund V, and FCM V is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The column titled &#147;Shares of Common Stock&#148; under &#147;Securities Beneficially Owned Prior to
Offering&#148; consists of (i) 1,569,488 shares of common stock received as consideration in connection with the Merger and (ii) 1,451,358 shares of common stock purchased on the Nasdaq Global Select Market prior to the Merger, held with J.P. Morgan
Securities LLC, each held directly by Foresite Capital Opportunity Fund V, L.P. (&#147;Opportunity Fund V&#148;). Foresite Capital Opportunity Management V, LLC (&#147;FCOM V&#148;) is the general partner of Opportunity Fund V and may be deemed to
have sole voting and dispositive power over the shares held by Opportunity Fund V. Dr.&nbsp;Tananbaum is the sole Managing Member of FCOM V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Each
of FCOM V and Dr.&nbsp;Tananbaum disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Prior to the Company&#146;s acquisition of ImmPACT, Cindy Xiong, a Partner at Foresite Capital
Management, LLC, was an ImmPACT Director from January&nbsp;14, 2022 through October&nbsp;31, 2024. The business address of Dr.&nbsp;Tananbaum, Opportunity Fund V, and FCOM V is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Handok Inc. is a publicly traded company listed on the Korea Exchange. Y&amp;S International Co., Ltd. as the
majority shareholder of Handock Inc., may be deemed to have voting, investment and dispositive power over the shares held by Handok Inc. The majority shareholder of Y&amp;S International Co., Ltd., Kim, Daniel Dong Han, is a related party to Handok
Inc.&#146;s Chief Executive Officer, Kim <FONT STYLE="white-space:nowrap">Young-jin.</FONT> The address of Handok Inc. is 132, <FONT STYLE="white-space:nowrap">Teheran-ro,</FONT> <FONT STYLE="white-space:nowrap">Gangnam-gu,</FONT> Seoul, 06235,
Republic of Korea. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Peter Choi, as the Chief Executive Officer of Hayan I, L.P., has voting, investment and dispositive power over
the shares held by Hayan I, L.P. The address of Hayan I, L.P. is 601 Gateway Blvd, Suite 360, South San Francisco, CA 94080, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc. (JJDC) is a wholly-owned subsidiary of
Johnson&nbsp;&amp; Johnson, a publicly traded company (NYSE: JNJ). As a result, Johnson&nbsp;&amp; Johnson may be deemed to indirectly beneficially own the shares directly beneficially owned by JJDC. The address of JJDC is 410 George Street, New
Brunswick, NJ 08901, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jonathan Jonas, as the Manager of JVC CPF LLC, has voting, investment and dispositive power over the shares
held by JVC CPF LLC. The address of JVC CPF LLC is 650 Dundee Road, Suite 380, Northbrook, IL 60062, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novartis Bioventures Ltd. is an indirect, wholly-owned subsidiary of Novartis AG. As the indirect parent of
Novartis Bioventures Ltd., Novartis AG may be deemed to beneficially own the reported securities. Prior to the Company&#146;s acquisition of ImmPACT, Michal Silverberg, an employee of Novartis Services, Inc., an affiliate of Novartis Bioventures
Ltd., was an ImmPACT Director for the period of May 2020 to October 2024. The Board of Directors of Novartis Bioventures Ltd. has sole voting and investment control and power over securities held by Novartis Bioventures Ltd. None of the members of
its Board of Directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Ms.&nbsp;Silverberg disclaims beneficial ownership of the securities held by Novartis
Bioventures Ltd., except to the extent of her pecuniary interest arising as a result of her </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
employment by an affiliate of Novartis Bioventures Ltd. The business address of Novartis Bioventures Ltd. and Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares are held of record by OrbiMed Israel Partners II, L.P. (&#147;OIP II&#148;). OrbiMed Israel GP II, L.P.
(&#147;Israel GP II&#148;) is the General Partner of OIP II, and OrbiMed Advisors Israel II Limited (&#147;Advisors Israel II&#148;) is the General Partner of Israel GP II. Advisors Israel II and Israel GP II may be deemed to have shared voting and
investment power over the securities held by OIP II, and each of, Advisors Israel II and Israel GP II may be deemed to directly or indirectly, including by reason of their mutual affiliation, be the beneficial owners of the shares held by OIP II.
Advisors Israel II exercises this investment power through an investment committee comprised of Carl L. Gordon, Erez Chimovits, and David P. Bonita, each of whom disclaims beneficial ownership of the shares held by OIP II. Prior to the
Company&#146;s acquisition of ImmPACT, Erez Chimovits, an employee at OrbiMed Advisors LLC, was an ImmPACT Director. Anat Nursella, an employee at OrbiMed Advisors LLC, was also previously the Chief Financial Officer of ImmPACT until 2022. The
address of OrbiMed Israel Partners II, L.P. is 601 Lexington Avenue, 54th Floor, New York, NY 10022, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bruce Edward Roberts, Ted (Byung Chan) Moon, Yaron Breski and Assaf Keret, as the Board of Directors of RMGP
Bio-Pharma General Partner Ltd., which is the General Partner of RMGP Bio-Pharma Investments L.P., which is the General Partner of RMGP Bio-Pharma Investment Fund, L.P., have voting, investment and dispositive power over the shares held by RMGP
Bio-Pharma Investment Fund L.P. The address of RMGP Bio-Pharma Investment Fund L.P. is 9&nbsp;Yehuda Halevi St, Tel Aviv, Israel. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Takeda Ventures, Inc. is a wholly-owned, indirect subsidiary of Takeda Pharmaceutical Company Limited, a
publicly traded company. Takeda Pharmaceutical Company Limited has ultimate voting, investment and dispositive power over the shares held by Takeda Ventures, Inc. Miles Gerson, Global Head of Takeda Ventures, Inc., served as a Director on
ImmPACT&#146;s Board until January 2022. The address of Takeda Ventures, Inc. is 500 Kendall Street, Cambridge, MA 02142, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Thomas Antunez, as Chief Financial Officer of Torrey Coast Ventures LLC, and Alan Braynin, as Chief Executive
Officer of Torrey Coast Ventures LLC, have voting, investment and dispositive power over the shares held by Torrey Coast Ventures LLC. The address of Torrey Coast Ventures LLC is 5930 Cornerstone Court W. Ste 240, San Diego, CA 92121, United States.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of venBio Global Strategic GP IV, LLC, the General Partner of venBio Global Strategic Fund IV, L.P., and
Corey Goodman and Robert Adelman, as Members of venBio Global Strategic GP IV, LLC, may be deemed to share voting, investment and dispositive power over the shares held by venBio Global Strategic Fund IV, L.P. Prior to the Company&#146;s acquisition
of ImmPACT, Richard Gaster, a Managing Partner at venBio Partners, LLC, was an ImmPACT Director for the period of January 2022 through October 2024. The address of venBio Global Strategic Fund IV, L.P. is 1700 Owens Street Suite 595, San Francisco,
CA 94158, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kim, Daniel Dong Han, as the majority shareholder of Y&amp;S International Co., Ltd., has voting, investment
and dispositive power over the shares held by Y&amp;S International Co., Ltd. The address of Y&amp;S International Co., Ltd. is 4F, 132, <FONT STYLE="white-space:nowrap">Teheran-ro,</FONT> <FONT STYLE="white-space:nowrap">Gangnam-gu,</FONT> Seoul,
06235, Republic of Korea. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_8"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate
in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be
registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the
depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made
with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a
book-entry security will not own such security directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street
name will be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor will hold only a beneficial interest in those securities through an account he or she maintains at that institution.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and
other financial institutions in whose names the securities are registered as the holders of those securities, and we or any applicable trustee or depositary will make all payments on those securities to them. These institutions pass along the
payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect
holders, not holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of
a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further
responsibility for the payment or notice even if that legal holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Whether and how the legal holders
contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check
with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise
in an applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may
not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section titled &#147;<I>Special
Situations When a Global Security Will Be Terminated</I>&#148; in this prospectus. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global
security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the
depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be
represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware
of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to
have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in an applicable prospectus supplement, the global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by such applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_9"></A>PLAN OF DISTRIBUTION FOR SHARES OFFERED BY SELLING STOCKHOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering for resale by the selling stockholders up to 37,499,981&nbsp;shares of common stock. The selling stockholders,
which as used herein include donees, pledgees, transferees, distributees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of our common stock or interests in our common
stock received after the date of this prospectus from the selling stockholders as a gift, pledge, partnership distribution or other transfer may, from time to time, sell, transfer, distribute or otherwise dispose of certain of their shares of common
stock or interests in our common stock on any stock exchange, market or trading facility on which shares of our common stock are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of
sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
selling stockholders may use any one or more of the following methods when disposing of their shares of common stock or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one or more underwritten offerings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares of common stock as agent, but may
position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its accounts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to their members, partners or shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the date of the registration statement of which this prospectus is a part is declared
effective by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">in-market</FONT> transactions, including transactions on a national securities
exchange or quotations service or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agreements with broker-dealers, who may agree with the selling stockholders to sell a specified number of
such shares of common stock at a stipulated price per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some shares of our common stock owned by them and, if
a selling stockholder defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell such shares of common stock from time to time, under this prospectus, or under an amendment or supplement to this
prospectus amending the list of the selling stockholders to include the pledgee, transferee or other successors in interest as the selling stockholders under this prospectus. The selling stockholders also may transfer shares of our common stock in
other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of shares of our common stock or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
short sales of our common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close
out their short positions, or loan or pledge shares of our common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial
institutions or the creation of one or more derivative securities that require the delivery to such broker-dealer or other financial institution of shares of our common stock offered by this prospectus, which shares such broker-dealer or other
financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate
proceeds to the selling stockholders from the sale of shares of our common stock offered by them will be the purchase price of such shares of our common stock less discounts or commissions, if any. The selling stockholders reserve the right to
accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of shares of our common stock to be made directly or through agents. We will not receive any of the proceeds from any offering by the
selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time a particular offering of securities is made, a prospectus supplement, if required, will be distributed,
which will set forth the name of the selling stockholders, the aggregate amount of securities being offered and the terms of the offering, including, to the extent required, (1)&nbsp;the name or names of any underwriters, broker-dealers or agents,
(2)&nbsp;any discounts, commissions and other terms constituting compensation from the selling stockholders and (3)&nbsp;any discounts, commissions or concessions allowed or reallowed to be paid to broker-dealers. We may suspend the sale of
securities by the selling stockholders pursuant to this prospectus for certain periods of time for certain reasons, including if the prospectus is required to be supplemented or amended to include additional material information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may in the future resell a portion of our common stock in open market transactions in reliance upon Rule 144
under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or pursuant to other available exemptions from the registration requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of shares of our common stock or
interests therein may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of shares of our common stock or warrants may be underwriting
discounts and commissions under the Securities Act. If any selling stockholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(11) of the Securities Act, then the selling stockholder will be subject to the prospectus delivery
requirements of the Securities Act. Underwriters and their controlling persons, dealers and agents may be entitled, under agreements entered into with us and the selling stockholder, to indemnification against and contribution toward specific civil
liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, our common stock to be sold, the purchase prices and
public offering prices, the names of any agent, dealer or underwriter, and any applicable discounts, commissions, concessions or other compensation with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if
appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate the offering of shares
of our common stock offered by the selling stockholders, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock. This may include over-allotments or short
sales, which involve the sale by persons participating in the offering of more shares of common stock than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open
market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of our common stock by bidding for or purchasing shares of common stock in the open market or by imposing penalty bids,
whereby selling concessions allowed to dealers participating in the offering may be reclaimed if shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of our common stock at a
level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Registration Rights Agreement, we have agreed to indemnify the selling stockholders party thereto against certain liabilities that they may incur in connection with the sale of the securities registered hereunder, including liabilities under the
Securities Act. In addition, we and the selling stockholders may agree to indemnify any underwriter, broker-dealer or agent against certain liabilities related to the selling of the securities, including liabilities arising under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Registration Rights Agreement, we have agreed to maintain the effectiveness of this registration statement until all securities
covered by the Registration Rights Agreement have been sold under this registration statement, have been transferred without restrictive legends, may be sold under Rule 144 under the Securities Act or are no longer outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders may use this prospectus in connection with resales of shares of our common stock. This prospectus and any accompanying
prospectus supplement will identify the selling stockholders, the terms of our common stock and any material relationships between us and the selling stockholders. Selling stockholders may be deemed to be underwriters under the Securities Act in
connection with shares of our common stock they resell and any profits on the sales may be deemed to be underwriting discounts and commissions under the Securities Act. Unless otherwise set forth in a prospectus supplement, the selling stockholders
will receive all of the net proceeds from the resale of shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A selling stockholder that is an entity may elect to
make an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of common stock to its members, partners or shareholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus. To the extent that
such members, partners or shareholders are not affiliates of ours, such members, partners or shareholders would thereby receive freely tradable shares of common stock pursuant to the distribution through a registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay all fees and expenses incident to the registration of shares of our common stock to be offered and sold pursuant to
this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orderly Disposition Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement, each selling stockholder may not sell more than ten (10%) of the average daily trading volume of
our common stock over the five (5)&nbsp;business day period ending on the business day immediately prior to the date of the proposed sale, other than pursuant to a block trade or other disposition through a market participant designated by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP will pass upon the validity of the securities offered by this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all the information set forth or incorporated by reference in such registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may
not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other
document. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that
the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. Because we are
subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the
SEC&#146;s website at <U>http://www.sec.gov</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx907660_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed
with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40502):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024007592/lyel-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023, filed with the SEC on February&nbsp;28, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2024, June&nbsp;30, 2024 and September 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024020467/lyel-20240331.htm">May&nbsp;
6, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024035617/lyel-20240630.htm">August&nbsp;
7, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024046285/lyel-20240930.htm">November&nbsp;7, 2024</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000119312524161601/d855288d8k.htm">June&nbsp;14,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000119312524168597/d808272d8k.htm">June&nbsp;
26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000119312524242808/d881076d8k.htm">October&nbsp;
24, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000119312524248760/d901554d8k.htm">October&nbsp;31, 2024</A>, respectively, in each case other than information furnished under Item 2.02 or
7.01 of Form <FONT STYLE="white-space:nowrap">8-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portions of the Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000114036124021008/lyel-20240614.htm">Schedule
 14A</A>, filed with the SEC on April&nbsp;
22, 2024, that are incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024007592/lyel-20231231.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock in <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1806952/000162828024007592/lyel-20231231.htm">Exhibit
 4.3</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus, which will become a part of this prospectus from the date that such documents
are filed with the SEC. Information in such future filings update and supplement the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any
document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier statements. We will furnish without charge to
each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including
exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LYELL
IMMUNOPHARMA, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 Haskins Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">South San
Francisco, CA 94080 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">695-0677</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth an estimate of the fees and expenses, other than the underwriting discounts and commissions, payable by the
registrant in connection with the issuance and distribution of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,396.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated expenses not presently known. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Indemnification of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law, authorizes a court to award, or a corporation&#146;s board of directors to grant,
indemnity to directors and executive officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our Restated
Certificate permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our Bylaws that provide that we will indemnify our directors and executive
officers and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and executive officers, whereby we have agreed to indemnify our directors
and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of
the fact that such director or executive officer is or was a director, executive officer, employee, or agent of Lyell, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer
reasonably believed to be in, or not opposed to, the best interest of Lyell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding
involving a director or executive officer of Lyell regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the
Exchange Act, that might be incurred by any director or officer in his capacity as such. Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers or persons controlling us, we
have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation by Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit/<BR>Appendix<BR>Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/d881076dex21.htm">Agreement and Plan of Merger, dated as of October&nbsp;
24, 2024, by and among ImmPACT Bio USA Inc., Lyell Immunopharma, Inc., Inspire Merger Sub Inc. and WT Representative LLC, solely in its capacity as the Representative </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40502</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;24,&nbsp;2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000119312521195237/d136326dex41.htm">Amended and Restated Certificate of Incorporation </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-257249</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;21, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000162828023037360/lyel-20230930x10qxexx32.htm">Amended and Restated Bylaws </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40502</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;7,&nbsp;2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000119312521185918/d168165dex41.htm">Form of Common Stock Certificate </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-256470</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165dex42.htm">Amended and Restated Investors&#146; Rights Agreement, dated as of March&nbsp;
5, 2020, by and among Lyell Immunopharma, Inc. and certain of its stockholders </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">333-256470</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;25, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/d901554dex101.htm">Registration Rights Agreement, dated as of October&nbsp;
31, 2024, by and among Lyell Immunopharma, Inc., each of the Sellers Party thereto and WT Representative LLC, solely in its capacity as the Representative of the Sellers </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40502</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;31, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d907660dex51.htm">Opinion of Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d907660dex231.htm">Consent of Independent Registered Public Accounting Firm </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d907660dex51.htm">Consent of Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP (See Exhibit 5.1) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d907660ds3.htm#sig">Power of Attorney (See signature page) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d907660dexfilingfees.htm">Filing Fee Table </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the
effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided,
however,</I> that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant
to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<I> bona fide</I> offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial<I> bona fide</I> offering thereof.<I> Provided, however,</I> that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to
such effective date, supersede or modify any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in
the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability of the registrant under the Securities Act, each filing of
the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange Act) that is
incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona
fide</I> offering thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of
California, on November&nbsp;29, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">LYELL IMMUNOPHARMA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lynn Seely</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lynn Seely, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>KNOW ALL PERSONS BY THESE PRESENTS</B>, that each person whose signature appears below constitutes and appoints Lynn Seely and Charles
Newton, and each of them, as true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full powers of substitution and resubstitution, for them and in their name, place and
stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and
generally to do all such things in their names and behalf in their capacities as officers and directors to enable Lyell Immunopharma, Inc. to comply with the provisions of the Securities Act, and all requirements of the SEC, granting unto said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as he or she might or could do in person, ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or any of
them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act, this registration statement has been signed below by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Lynn Seely</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Lynn Seely, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Charles Newton</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Charles Newton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Financial and Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Richard D. Klausner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richard D. Klausner, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chair of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Otis Brawley</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Otis Brawley, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Catherine Friedman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Catherine Friedman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Elizabeth Nabel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Elizabeth Nabel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Robert Nelsen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Sumant Ramachandra</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sumant Ramachandra, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ William Rieflin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">William Rieflin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">November&nbsp;29, 2024</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d907660dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center">S<SMALL>KADDEN</SMALL>, A<SMALL>RPS</SMALL>, S<SMALL>LATE</SMALL>, M<SMALL>EAGHER</SMALL>&nbsp;&amp; F<SMALL>LOM</SMALL> <SMALL>LLP</SMALL></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ONE MANHATTAN WEST</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NEW YORK, NY 10001</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TEL: (212) <FONT STYLE="white-space:nowrap">735-3000</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FAX: (212) <FONT STYLE="white-space:nowrap">735-2000</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.skadden.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FIRM/AFFILIATE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OFFICES</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BOSTON</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CHICAGO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HOUSTON</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LOS ANGELES</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PALO ALTO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WASHINGTON, D.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WILMINGTON</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BEIJING</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BRUSSELS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FRANKFURT</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HONG KONG</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LONDON</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MUNICH</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PARIS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S&Atilde;O PAULO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SEOUL</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SHANGHAI</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SINGAPORE</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TOKYO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TORONTO</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:66%; font-size:10pt; font-family:Times New Roman">November 29, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyell Immunopharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">201 Haskins Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Lyell Immunopharma, Inc. Registration Statement on
Form</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;S-3</FONT></U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special United States counsel to Lyell Immunopharma, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in
connection with the resale by the selling stockholders identified on <U>Schedule A</U> hereto (the &#147;<U>Selling Stockholders</U>&#148;) of up to 37,499,981 shares (the &#147;<U>Shares</U>&#148;) of the Company&#146;s common stock, par value
$0.0001 per share (the &#147;<U>Common Stock</U>&#148;), issued as part of the merger consideration pursuant to the Agreement and Plan of Merger, dated as of October&nbsp;24, 2024 (the &#147;<U>Merger Agreement</U>&#148;), by and among the Company,
ImmPACT Bio USA Inc., a Delaware corporation (&#147;<U>ImmPACT</U><U> Bio</U>&#148;), Inspire Merger Sub Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), and WT Representative LLC,
a Delaware limited liability company, solely in its capacity as the representative, agent and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> of ImmPACT Bio securityholders (the
&#147;<U>Representative</U>&#148;), pursuant to which the Company acquired ImmPACT Bio through the merger of Merger Sub with and into ImmPACT Bio, with ImmPACT Bio surviving the Merger as the surviving entity and the Company&#146;s indirect, wholly
owned subsidiary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyell Immunopharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 29, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act of 1933 (the &#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
rendering the opinion stated herein, we have examined and relied upon the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> of the Company relating to the Shares filed on the date hereof with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act allowing for delayed offerings pursuant to
Rule 415 of the General Rules and Regulations under the Securities Act (the &#147;<U>Rules and Regulations</U>&#148;) (such registration statement being hereinafter referred to as the &#147;<U>Registration Statement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the preliminary prospectus, dated as of the date hereof, which forms a part of and is included in the Registration Statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) an executed copy of the Meger Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) a specimen certificate evidencing the Common Stock in the form of Exhibit 4.1 to the Registration Statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) an executed copy of a certificate of Matthew Lang, Chief Business Officer, Chief Legal Officer and Corporate Secretary of the Company, as
of the date hereof (the &#147;<U>Secretary&#146;s Certificate</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) a copy of certain resolutions of the Board of Directors of
the Company adopted on October&nbsp;22, 2024, certified pursuant to the Secretary&#146;s Certificate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) a copy of the Company&#146;s
Amended and Restated Certificate of Incorporation, as in effect as of the date of the issuance of the Shares and as of the date hereof, certified by the Secretary of State of the State of Delaware as of November&nbsp;27, 2024, and certified pursuant
to the Secretary&#146;s Certificate (the &#147;<U>Amended and Restated Certificate of Incorporation</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) a copy of the
Company&#146;s Amended and Restated Bylaws, as in effect as of the date of issuance of the Shares and as of the date hereof, and certified pursuant to the Secretary&#146;s Certificate (the &#147;<U>Amended and Restated Bylaws</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and the
Selling Stockholders and such agreements, certificates and receipts of public officials, certificates of officers or other representatives of the Company and the Selling Stockholders and others, and such other documents as we have deemed necessary
or appropriate as a basis for the opinion stated below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we have assumed the genuineness of all signatures, including
electronic signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic,
certified or photocopied copies, and the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyell Immunopharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 29, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authenticity of the originals of such copies. With respect to our opinion set forth below, we have assumed that (i)&nbsp;the Company received the consideration for the Shares set forth in the
Merger Agreement and the applicable board resolutions and (ii)&nbsp;the issuance of the Shares has been registered in the Company&#146;s share registry. As to any facts relevant to the opinion stated herein that we did not independently establish or
verify, we have relied upon statements and representations of officers and other representatives of the Company and the Selling Stockholders and others and of public officials, including the facts and conclusions set forth in the Secretary&#146;s
Certificate and the factual representations and warranties set forth in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not express any opinion with respect
to the laws of any jurisdiction other than the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon
the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that, the Shares have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and have been validly issued
and are fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in rendering the foregoing opinion we have assumed that, at all applicable times: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Company&#146;s issuance of the Shares did not (i)&nbsp;except to the extent expressly stated in the opinion contained herein, violate
any statute to which the Company or such issuance is subject, or (ii)&nbsp;constitute a violation of, or a breach under, or require the consent or approval of any other person under, any agreement or instrument binding on the Company (except that we
do not make this assumption with respect to the Amended and Restated Certificate of Incorporation, the Amended and Restated Bylaws or those agreements or instruments expressed to be governed by the laws of the State of New York which are listed in
Part II of the Registration Statement or the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 although we have assumed compliance with any covenant, restriction or provision
with respect to financial ratios or tests or any aspect of the financial condition or results of operations of the Company contained in such agreements or instruments); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company&#146;s authorized Common Stock is as set forth in the Amended and Restated Certificate of Incorporation, and we have relied
solely on the certified copy thereof issued by the Secretary of State of the State of Delaware and have not made any other inquiries or investigations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion letter shall be interpreted in accordance with customary practice of United States lawyers who regularly give opinions in
transactions of this type. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyell Immunopharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 29, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 4 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference to our firm under the heading &#147;Legal Matters&#148; in
the prospectus forming part of the Registration Statement. We also hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the
category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules and Regulations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TWG </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="41%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Total Number of Shares to be Sold</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arkin Bio Capital LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>932,248</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bukwang Pharmaceutical Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1,410,071</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CFAM 2017 LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>27,232</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2,745,001</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decheng Capital Global Life Sciences Fund IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5,795,032</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excellent Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>108,928</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund V, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4,225,547</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Opportunity Fund V, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1,569,488</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Handok Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>239,642</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hayan I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>477,311</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>823,317</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JVC CPF LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>119,329</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Bioventures Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3,241,716</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Israel Partners II, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3,103,623</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMGP <FONT STYLE="white-space:nowrap">Bio-Pharma</FONT> Investment Fund L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2,633,679</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeda Ventures, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>823,317</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Torrey Coast Ventures, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2,056,955</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">venBio Global Strategic Fund IV, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7,102,190</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Y&amp;S International Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>65,355</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>37,499,981</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d907660dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in the Registration Statement
<FONT STYLE="white-space:nowrap">(Form&nbsp;S-3)</FONT> and related Prospectus of Lyell Immunopharma, Inc. for the registration of 37,499,981 shares of its common stock, and to the incorporation by reference therein of our reports dated
February&nbsp;28, 2024, with respect to the consolidated financial statements of Lyell Immunopharma, Inc.,&nbsp;and the effectiveness of internal control over financial reporting of Lyell Immunopharma, Inc., included in its Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023, filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Mateo, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;29, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d907660dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:lyel="http://www.ly.com/20241129" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31">
<head>
<title>EX-FILING FEES</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P11_29_2024To11_29_2024" id="ixv-431">0001806952</ix:nonNumeric><ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="P11_29_2024To11_29_2024" id="ixv-432">EX-FILING FEES</ix:nonNumeric><ix:nonNumeric name="ffd:OfferingSctyTitl" id="hidden126672726" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis">Common Stock, par value $0.0001 per share</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"/></ix:references><ix:resources><xbrli:context id="P11_29_2024To11_29_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-29</xbrli:startDate> <xbrli:endDate>2024-11-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806952</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-29</xbrli:startDate> <xbrli:endDate>2024-11-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Calculation of Filing Fee Tables </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="ffd:FormTp" contextRef="P11_29_2024To11_29_2024" id="ixv-458"><ix:nonNumeric name="ffd:SubmissnTp" contextRef="P11_29_2024To11_29_2024" id="ixv-459">S-3</ix:nonNumeric></ix:nonNumeric></div> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Form Type) </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P11_29_2024To11_29_2024" id="ixv-460">Lyell Immunopharma, Inc.</ix:nonNumeric> </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Exact Name of Registrant as Specified in its Charter) </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Table 1: Newly Registered and Carry Forward Securities </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:99%;border:0">
<tr>
<td style="width:13%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:18%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:7%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Security&#8194;<br/>Type&#8194;</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Security Class&#160;Title</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fee<br/>Calculation<br/>or Carry<br/>Forward<br/>Rule</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount<br/>Registered</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Proposed<br/>Maximum<br/>Offering<br/>Price Per<br/>Unit</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Maximum<br/>Aggregate<br/>Offering Price</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fee Rate</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount of<br/>Registration<br/>Fee</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carry<br/>Forward<br/>Form<br/>Type</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carry<br/>Forward<br/>File<br/>Number</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carry<br/>Forward<br/>Initial<br/>Effective<br/>Date</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Filing Fee<br/>Previously<br/>Paid in<br/>Connection<br/>with Unsold<br/>Securities&#160;to<br/>be Carried<br/>Forward</div></div></td></tr>
<tr style="font-size:1pt">
<td colspan="25" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td colspan="25" style="padding-bottom:1pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt; padding-right:2pt;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Newly Registered Securities</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="padding-bottom:1pt ;BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: -0.67em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" format="ixt:fixed-false" id="ixv-461">Fees to be&#160;Paid</ix:nonNumeric></div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" id="ixv-462">Equity</ix:nonNumeric>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Secondary&#160;Offering:&#8201;</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="-sec-ix-hidden:hidden126672726;display:inline;">Common&#160;Stock,&#160;par&#160;value&#8201; $0.0001 per share</div>&#8201;</div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8194;&#8201;<ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" format="ixt:fixed-true" id="ixv-463">457(c)</ix:nonNumeric>&#8195;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;"><ix:nonFraction name="ffd:AmtSctiesRegd" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-464">37,499,981</ix:nonFraction><div style="font-size:75%; vertical-align:top;display:inline;font-size:7.5px">(1)</div>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8194;<ix:nonFraction name="ffd:MaxOfferingPricPerScty" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-465">0.94</ix:nonFraction><div style="font-size:75%; vertical-align:top;display:inline;font-size:7.5px">(2)</div>&#8201;&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">$<ix:nonFraction name="ffd:MaxAggtOfferingPric" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-466">35,249,982</ix:nonFraction>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;"><ix:nonFraction name="ffd:FeeRate" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-467">0.0001531</ix:nonFraction>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8201;$<ix:nonFraction name="ffd:FeeAmt" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-468">5,396.77</ix:nonFraction>&#8194;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8195;&#8194;&#8195;&#8195;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8195;&#8194;&#8195;&#8195;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8195;&#8194;&#8195;&#8195;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="padding-bottom:1pt ;BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: -0.67em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Fees Previously Paid</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td></tr>
<tr style="font-size:1pt">
<td colspan="25" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td colspan="25" style="padding-bottom:1pt ;BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000; padding-left:8pt; padding-right:2pt;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carry Forward Securities</div></div></td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="padding-bottom:1pt ;BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: -0.67em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Carry Forward Securities</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top;white-space:nowrap;text-align:center;">&#8212;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap"><div style="font-weight:bold;display:inline;">Total Offering Amounts</div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:top;white-space:nowrap;text-align:center;"> <div style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;text-align:center">$<ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="P11_29_2024To11_29_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-469">35,249,982</ix:nonFraction>&#8201;</div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;text-align:center">$<ix:nonFraction name="ffd:TtlFeeAmt" contextRef="P11_29_2024To11_29_2024" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-470">5,396.77</ix:nonFraction>&#8201; </div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total Fees Previously Paid</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="P11_29_2024To11_29_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-471">&#8212;</ix:nonFraction>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total Fee Offsets</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="P11_29_2024To11_29_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-472">&#8212;</ix:nonFraction>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:0.75pt">&#160;</td>
<td colspan="8" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:0.75pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:0.75pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="7" style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Net Fee Due</div></div></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="padding-bottom:1pt ;BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;">$<ix:nonFraction name="ffd:NetFeeAmt" contextRef="P11_29_2024To11_29_2024" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-473">5,396.77</ix:nonFraction>&#8201;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="ffd:OfferingNote" contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis" escape="true" id="ixv-416">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the $1.88 (high) and $0.98 (low) sales price of the registrant&#8217;s common stock as reported on the Nasdaq Global Select Market on November&#160;22, 2024, which date is within five business days prior to the filing of this registration statement. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Shares of common stock registered for resale pursuant to this registration statement are shares which are to be offered by the selling securityholders named herein. In the event of a stock split, stock dividend or recapitalization involving the common stock, the number of shares registered shall automatically be adjusted to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act of&#160;1933, as amended. </div></td></tr></table></ix:nonNumeric></div></div></div></div></div> <div>&#160;</div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g907660g03k03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g907660g03k03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[1A04&AO=&]S:&]P(#,N,  X0DE-! 0
M     #P< @   @  ' )0  AR<C0R,S0Y-!P"!0 C36EC<F]S;V9T(%=O<F0@
M+2!);G-P:7)E("T@4RTS+F1O8W@X0DE-!"4      !#/9LSW87?QNY_R_W4@
M6BYT.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  8     $  0!@     0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M            =    )P    & &< ,  S &L ,  S     0
M           !              "<    =                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    =     !29VAT;&]N9P   )P    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   '0     4F=H=&QO;F<   "<     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    %.$))300,      W8     0
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ Q     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L
M @    D   "QAVD !     $   "\    Z    &     !    8     %!9&]B
M92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-#HQ,3HR." P.#HU,CHQ
M,0!R<C0R,S0Y-      #H $  P    '__P  H ( !     $   "<H , !
M  $   !T          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!3D5X:68
M $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M"0   +&':0 $     0   +P   #H    8     $   !@     4%D;V)E(%!H
M;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(T.C$Q.C(X(# X.C4R.C$Q ')R
M-#(S-#DT      .@ 0 #     ?__  "@ @ $     0   )R@ P $     0
M '0         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              !(
M     0   $@    !_^$_/&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M*"@H*"C_P  1" %J >@# 2(  A$! Q$!_\0 '  !  $% 0$
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MWNW@;U'^AWJ7U]@4A.]-%^RJ?@VB.QI8OV5@UD^\?S_N3K7\SSGB&V#G5?\
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M^B9H U8=D<\A;;PWQ$RIC;#5.BB<QK0W+MW%;,+JO>_"O6DC&[&[5W5[HVH
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M.!'!&UC!R#1@+Z8SNK@L#H54QJ6D44QNJDIA4("&T,.05<K6<BKD 1$0!$1
M$1$ 0\D0\D!8?,@W!VW5PRJ;H"@!ZE>>KMU)6L<RJ@CE8<9#QG.%ZN85N"!C
MHBVX(:4EHR+^+.ST2E]1;?8M.UHD>6M8<GJ.2CQ\51;JIU/4MD<&#=V"!OOU
M726%A>(N'*:]P/BJ7S-#G!Q[MP'+T@JQ&_7:?!R,GI<9?'3LR&J>:>D>R:FF
M<W&''0>2D'A/B]DT4=/5=\96L)=(]PP=_P":T^X6&X<.R.:^#302DF61[VN<
M&#J,'P/@O(^@;50-EH]4D+CEKB0,_2L9P]8\%&FRRB6W/L3RQ[7[M<'#K@Y5
MPPHJX1XL?2SB"J[ED+WY<0QQ(&/,5)U'4Q5=/'-"[4QXU X(R/G6D[V/DPNC
MK'D^_F5 / JH.1OS3 4%CD\EQHH:R$QRQL=G'MAE1I=Z&2V5[W [&1QCT@C3
M@[?<I5(:1N2L5?K:VX4<F=>MC'!@:0,DCKGT+E=2P%D0<X>9%K&O=;T?!A.$
M+WWK6TU0Y[GM:YQ<YPQS6X-.0"-P5$-93S6ZK?&6 / &02#S]"D#AB\LK*?0
MYS=3=+,!I'15>DYS?^GN\R-F32DN^/!L&,A <[(/%.J[ZW*)4=40(I 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 #R5H\,\E<>2M\_B@&535C.>2KCR"O!=ZQE'1
M2.)(<6.T[9W 6%DU7%R?")2UEHC!\8781Q/I89"R3R7:V28*P=CACI(ZBOKM
M#3#B5HF !?C)."5C@XW>XZI=R6XVVY+7N+N)7W#N:"A<"UH=!(',QX#8_,5P
M^GT2ZGE/(GY(F?4<R/3J>U>9E...)ZB\7"6FMWLAD0+7@0RES=FX. /.5L7
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MD[9Y*0J6IAJ& Q31O)_LO!0'W!SR^=-]7+94SC. @SR_>@+@0>2*G(X YJJ
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MW@#^T5D1Y7S+'6$@T /]XK(8P@K\J*_4JJWFKD,PB(@"(B BWMS]QM/Q9_\
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MC=#G%7-_D1>I 3SE"5#_  KV@5]SKY(9JB5P;$7[PQCJ!T]*EV-VJ)KNI *
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MBF[LMU@G!.>N%DOU2LJ[(V14H/9D2BXO1E6JJHWEE56P@(B( B(@"(B (B(
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-1$ 1$0!$1 $1$!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g907660g08k08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g907660g08k08.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_[1PR4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :X/OH         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ #<'WP  0 ! -P??  !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              *X   %;     8 9P P #@ :P P #@    !
M                      $             !6P   *X
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   *X     %)G:'1L;VYG
M   %;     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   "N     !29VAT;&]N9P  !6P    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
M$;$    !    H    %    '@  "6    $94 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %  H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M4L7KUM^35C/Z7FTOL^D]];?39S[GW"S;M]JY+_F)]9_^Y5/_ &_=_P"DDO\
MF+]9XC[53'A]HN_])(^SB_SH^Q5^#K]9;U 9V0<1G5F.>\ .QRQ^/]"O==36
M][+/:UO\W[*O75K ZCDX LQQT_JN8PN+AD9'IO>YT06MFRMM=&UC=G\MZY*_
MZM]4Q[33=U&AEK=-ANR9/T?H11^D^FWZ"C_S?ZF6EPZA2X .<8LRB8:UUSH_
M5_\ 1UO2]K'_ )T?8JSV?2\3(.3C5WFJS'-@GTK@&V-\K&M<]O\ TD'J.;D8
M8J=3AVYH<XBT4ENYC0USM^VUS&V>_97LWKS^KZJ]:NR/LU6=2^X-+RT79'T0
M=L[C1M^D59_YB?6?_N53_P!OW?\ I)#V<7^='V*^CU)^L.6#(Z-G%FT.^BS<
M#,.8YGJ_N_N/>C#J^991DV4],R/4H<QE55NVLVEQVO=6[<]K:J_I[WKD/^8G
MUG_[E4_]OW?^DDO^8GUG_P"Y5/\ V_=_Z21]G%_G1]BK\'K*.O9%MU=+^DYU
M3K'!CGN97Z;)$E[[!=_-L_>:Q3ZF[)RNAM>W'R!D6BE[L:BWT;FDOK?97]I$
M;/2_PW^D9^C7(?\ ,3ZS_P#<JG_M^[_TDE_S$^L__<JG_M^[_P!))>SB_P Z
M/L5?@ZM?VZO(K+:^N6-)V[;G4FOWM]%OJ[=S]E;;'7;_ /25,]3](M/JF'?B
M]#9CU/SLNZM]<68U@;D.@_2=9;^C]/;_ #S?\(N7_P"8GUG_ .Y5/_;]W_I)
M0L^I7UAI;NMS<>MO[SLBX#C=WJ_="7M8_P#.C[%6>SJ-.8:PU]/7MP<TFS?4
M2T5L?4WT_<QMGK?:/4L]2K^=K_T6.KW3^E96;1:;LWJV*\.],B]]=9) :_UL
M?T#=^CW.V_I'O_PG_!KEC]6>IAI=^UL+:WD_:[=/H_\ !_\ ",4G_5;JS(W]
M4PV2)&[+M$B=NX37]'<U+VL?^='V*L]GT'I^"<*I];LB[*+WE_J7NW.$@-V-
M@-VL;M5I>9O^JW5F3NZGB"#M/ZU;H8W[=*OI;1N5OIWU.Z]]HQLMF;CW8]=U
M=CG5Y%KPYM;VFP-_1[7?0<U X<?^='V*U[/_T/0LK!ZW;F/LQ^J#&Q3&R@8[
M'N$ ?X>QQ]KW_P#!HN-C=4KRC;DYK;L<^I% J#8W.:['_3!V[]!4U]?T?TGJ
M*RZS':XM=8UKN[2Z#]T^:=IJL;NK<'MF):9$@P>$E-3[)U3;'VZ'>/IM/:#S
M_G*5./U%E[7VY0?2)W5;!KI _2?2]KE8;;CO(#;&N)X =/GXJ>T?ZE)35NQ^
MHNCTLL5F")-8(F7:[)]WM<S\_P#P?_"(F)5EU@_:;A<>T-#>[G=OY+F,_P"M
MJAD]89CEH?9CM<]I<T.?8 =KW-L]_I.VM;56[_KRNX&37EXXL#FO<T[;/3+B
MP.@/AKK QSO8]J27+S,AM>=>/6VEGTZW9IJYB7,H<WV;*K&V?397_;5<6M-N
MRW,-7IO(L8.H'<)T=[+:VV;*OS-RU;<IPO=6,"R[8_9ZH#"""T.]22[Z#?YO
M_2_\'Z?T&MR&-=[^FV/VEKVD,K<0Z=V[Z>W<UQW;V/\ ^VTE(.F=48'BFZZB
M';9(R?6=ZC@QC:JVGW_])_Z5%ZU1U6[TOL#G!HGU&L<&.G38=Q+?;])'QK\6
M\'?C_9X( %H8).[Z+=KG?1M_Z:#U?KW1NB^E^TLCT#?/I-VO>YVV-YV4ML=M
M;N^DB 2: L]@LR0$XF))%]8Z%ROL/UE_>N_[?'_I1+[#]9?WKO\ M\?^E$7_
M )_?5#_N:[_MF_\ ](IV_7SZHN>UOV[:7$-!=5<UHG]][ZFL8W^4]/\ :R?N
M2_Q2P?=(_OS_ ,9#]A^LO[UW_;X_]*+;Z35G58@;G.+K=SBV3N<&_FM>_P#.
M<K>UO^I*6T?ZDJ-?CP"$N(2D=*]1T9(&6]C*'E\@%KA+6&R/:?=L#7_])%VC
M_4E"R18RISZG!A:"2YP+M #VW,_.29G&KMI#VL;F7MM<_:+'8@!CPW?9_8VQ
M]E6][O\ 1_X),;L1X+W9=KFN;%9^QB0)=[O=C^[U&^S^W_PB)7U;,L: RZLN
MD#<['O&CBUM7M8Y_Z3<[WLW)-ZMED$&ZHN:"YT8^0!# ]]L;W,W6;&?HF))8
M,;6ZSTSEVO>'M;8VS#;MU<:W?1H9_.;-GJ_R-]GZ-:6#U3#R7BG'8]FA< ZL
ML$?ZN57$R^JY;WBJVC:QK=VZJUI#C/&^SW?1^C^8K^(W/!?]M=4X:>GZ(>(Y
MW;_4<[=^8DI__]'T>[I'2KLAV3;0Q][G!SK#,R&BOQ^CM8SV?R$?&QL3#I]'
M%K937N+MC  -SCO>[^LYQ4K+'LW;6[BT2&CDF)V_VE2_:F3('[.R(()F&1/Y
MGY_Y_P#T/W$E)J>F=,QWM?3176ZL;6%H VB=VUG[C=WO_KJWN;XA9PZIDN.T
M=.R 8F7!@;]%SXW>H[\YOI_1_/4F]0RW.</L%H8T [Y;[OI?S3';7_F_X7T4
ME-;)IZB;6.J%Q;L+7[<EK1]-SAH^M_OV?GM_XO\ P:T,#U&8K&7-+'LE@W/]
M1SFM.RNVVS\ZVVMK;+%7'4LLR1TZ[:UQ:22P.( G>QA?[F[O;^^F;U7(<-S>
MG9,>[EK&F&G;]%]K?I?F))19/2!D9+[2W%+'NW2ZIQL^CMES_6:QSM^W\SZ"
M$SH+2?TU>(]KG OV5;/;(]K-7>G[6M_U_2JX_J62SC N?)<!MV_FG:UWTOH6
M-][/^H2_:65 /V"\[FAT-V2 1J'[GL_2-=[?3;O24D/2^EF_[3Z#!?)/JM]K
MY/TCO;#O<J/U@^JW2OK :79CK*[<?<&6TN#7;71NK?O;8US/;^ZM"C*LNK+W
M4/H()&RT#= _/]CG^URK=9ZEDX/I>C6UPLG<]X) CAGMV^YR;/,,,3D)(X>L
M=]?2F,#.0B-RX/\ XV/U?_[E9?\ VY7_ .D$[?\ %E]7 ]I??E6L!!=6ZU@:
MX#\Q_IU,LVN_D/5['^L&?9D5UFJMX>X-+6M<'03K!+G?170]T<'/G,"83EZ=
M#>B<F*6,@2K58%@  ( ' 3[F^(2216*W-\0J^;+J2&"QQUTI<&N^B[\YSF_^
M=JPH7.M8V:J_5=K[9#>W[Q_E)*<0TY\NTZBQK ?38+:73&T1ZC][G;I_/_<]
M3U%-U6;8"X_M!D P/4I'#2&?0#G?I?\ SXKGVWJAK)'33O'#3=6 1[OHN;N_
M=;]+]]2=E]1#9;@;G2-/5:-""7N_L.VL22UL.G)M<ZK(^V4-# -]EK3)W>KM
MW4CZ?O\ 3W[OYG_A%?Q,9N,QS/7LOW&9N?O(T#8:?DIXS[K*0^^GT+"3->X/
MB##?>SV^YON1$D/_TNXMNZX+K0WU@P6/%89566[-Q]*'N.YWL_DIO6ZY'TLB
M?^(JC_JU:R^H]9JRWT8O2CD4MC;DF^NMKM Y_L.^[<WZ'T%.G-ZI;E-J=TXU
M8Y?8'9#[F0&L.VIPJ8'6.??]/9]!G^F4G'_5BESK<CZR!P] 6N;&I?54TS/\
MDN_-4/M/UK_<?_F5K5^V]2VR.GF=-/5;W'F/WE.K,SK+VUV81KJ=.Z[>T@:2
MWV0U_N=[4O<'[D?L4X_VGZU_N/\ \RM+[3]:_P!Q_P#F5K9NR\ZN/3PG6R)(
M#V S+AMU]GYK/S_\(B8E^1<";\=V.1V<YKIU<--G\@,?_;2]P?N1^Q3A?:?K
M7^X__,K2^T_6O]Q_^96MC+RK:<6^UKFM-5C6M+F/@ FO1\>ZSZ?\[5[/\Q4C
MU?(#*B;62]H>]PHN=+?=ZFS:-K+/99[+?H?H=_\ /I>X/W(_8IJ?:?K7^X__
M #*TOM/UJ_<?_F5K7MZQA5/<QQL+FO-9#:WN]P:RV/8UWTFVMVO^@J_6.HY^
M*^H8U7L>V7/+"[7_ $?M^@C&?$:$(_8KZ-#[3]:_W'_YE:7VGZU_N/\ \RM-
M^W.L?N#_ +:=_>G9UOK)L:!4+"2!L])PGRW3[4^C^[!2OM/UK_<?_F5I?:?K
M7^X__,K72INZC]P?N1^Q5O-_:?K7^X__ #*TOM/UK_<?_F5KI4.Y]C&S76;7
M?N@@=OY27N#]R/V*MY[[3]:_W'_YE:7VGZU_N/\ \RM:PS\\N(/3K0T-+MWJ
M5<@%WI_SGTG>UG]=)V=GC<!TZTG3;^DJ@D\S^D]NU+W!^Y'[%.3]I^M?[C_\
MRM3HR/K.;ZA:Q_I%[19[*_H[AO\ ^BMO%OON:3=CNQB.&O<UT_\ ;3GHZ7N#
M]R/V*M__T_1W9>0'N:"V&N(^AY_\=[E(79!'\]1KV(,_^?%7?78Y]A?6XM<]
MPD-.Z!]&/Y"7IV?Z-S0= T-=_P!/V?N.]J26R;<D"3=0 .\'_P!*)>KD$2+J
M"..#_P"E%4%3P-IK? ,@AI.@/FW_ +ZD:7%CMU3W02Z&M(()_=W?U??L24VQ
M;D'B_'/R/;_KB1NR 8-^.#X0?_2BK&MX>/T;APX[6F."=O']C:HLK>)(K?M(
M.YNT@3K]%I9YI*;7K7@$^OCP.=#_ .E$YNO DWXX Y,'_P!**J:[BTG8XD^V
M'-<1H#X ?G?01!B6O:',&T$ $/):=.7%NP_UDE)C=D#F_'&L<'GP_G$O6O\
M]/C_ ''_ -*(;L*\\;(C7W'7O[O;[O<F^PW@$-%<:[9)TUX^A^[[4D)?6OX]
M?'T\CV_ZXF]>^2/7QY&I&O'_ &XH#!MWR=I!D$DR8(_J-2;A7^T$M: (+FN.
MZ=>Y;_*24D]:_P#T^/IKP?\ THF]:^8]?'GP@_\ I1..G5:%SG.([G;S&W]Q
M/]@KD'>XQ'(:9@SK+$E,?6OB?7QX')@_^E%-IS'#<VREP\0UQ_[^D,&L1#W>
M?T?=YO\ 9[D]>&*W!S;;-"3MD;=?%H :DI49W[]7^:[_ ,FE&?\ OU?YKO\
MR:L))*:\9W[]7^:[_P FE&=^_5_FN_\ )JPDDI__V0 X0DE-!"$      %<
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
MG0$[  (    )    L8=I  0    !    O    .@   #<     0   -P    !
M061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,3$Z,C@@,#@Z
M-3<Z,S, <G(T,C,T.30      Z !  ,    !__\  * "  0    !   %;* #
M  0    !   "N          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4Y%
M>&EF  !-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L
M @    D   "QAVD !     $   "\    Z    -P    !    W     %!9&]B
M92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-#HQ,3HR." P.#HU-SHS
M,P!R<C0R,S0Y-      #H $  P    '__P  H ( !     $   5LH , !
M  $   *X          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M*"@H*"@H*"@H_\  $0@#M0=D P$B  (1 0,1 ?_$ !T  0 !!0$! 0
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M B(@(B("(B B(@(B("(B B(@(B("(B B(2@(J9\$R@JB!$!$1 1$)0$5,JJ
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MKY2>C;'I_3]'<+30,IZNIKMV61O-P+7D_$!==L'T389-(V6_/M\9N@&_T_\
M6WN'%;K#5M5%6F;L7K(4,[6=LD>F*\6BP4[:VY\=\[WFQG. ,8.3P/<N'BVV
M:SLM3#+J2R8HY2" YG1$M[<'!RI&&2,,OI[(3(6ATEJ:WZHT_%=[=(#2OSO9
M/T".8*AS7^WLT=VDMNDZ1M6]AW.L.=P+NT!N./BI$3*1$R^@<CO7-;0M4#2&
MF*N\.IG50@Q^:#]W.3WX*@:U[>M1VNXPC5%I::9YXX'1. [QYIRI#VR7>GON
MQ6HN=%O=7JHF2LWA@X)'!73ON4Z?95KANN[!+<FT3J,,E,6X9-_..W. NTRO
MC?9OM+NNE]+NLVGK::FODE,SI,[P:WNW<<??E2;LCVUU-_OC+-J.GCCJ9W!L
M,L9P-[.-TMQWD=JLX)A9PI[R$R%"6V/:Q<]$ZII[?14L4M.^%LKG..#Q)SV'
MN7$7?;SJA\O7K=:F4]JW@&F0;X<?[6 I&&933+ZDR$R%Q&RC74&NM/==;'T-
M5"[HZB(.SNNQGG@=A"X/:EMQCL5QEM.FZ=M771/#))G.\UI[6@8.>SM4C#,S
M14IS7-[0-2C2>F:J[NIC5"#CT8?NYX'MP>Y0-9-OU^MURCCU3:VNIG\3N_FG
M-'8?HG*D7;'=J.^[&ZRXVZ5LM-.P/:X'EEIX>]73-[E.EV5ZV;KJPON3:(T8
M;(6;ADW\X)&<X'<NS4*?)?E9!L[J99G!L<<SG.<>P9*YO6>WVLDNSJ+1U$R:
M)I($[CO=+[FXX>/:DX=ZA:WV?1^4ROG31&WVJ%V9;]8T38&2/#34-.[T>>'%
MN._MRIPU!J.WV/3T]YK9FBCCCWVNS]+/(#WJ3$PE3#=Y"97RU6;?-47&Y2FQ
M6N-M*WE'CI';O>3@+)?\H6[355##3VN*%[BV.</DSYQ=CAYO=A71*Z9?3F4R
M%#&U3:5?-'-L=7!1PRT%?$USW./T7$ D<O[2E#35Z@O>G*&[0N AJ8&3<#]'
M(SA2F:;=%!NBMK-XU9M&DL]MHXC:F2/)FWLGH@>!Y=HPIQXXXI,4LQ2J(BB"
MP[I6-M]OJ*N1KG,A87D#F<+,6FUA_P!&+G_V+D@<ILRVH4&O:JJIZ&AJ*9U.
MS>)E((/$=WO4AA?,/R33NW:]'&<09^+5DU/R@+I0:@N=)4VV*6"":6&,-DP2
M6OP/ZOL6IP[U#4X=ZA]+9"9"^6Z7;WJ>W7:/\O6R/JKB"8L=&X-SS!P?W+Z$
MKM56NCTJ[4,LX%M$72AX[1[/:I.&828IOSQ48[4]JK-"7BBH'VM]9UF-L@>)
M=S=RYS>6#^JHKN.WO4MQNLHT[;&=48>#,=(XM[R<#"X?:7KJ37%TM-1549I*
MRF8V&5N]O D/<>X8^DM1@GY:C#R^C=J&U :+L=LJX[<^JGKFL>UG2;C6@@GB
M<'N[EU>@-31ZNTO1WB&!T G!S&XY+2"0>/V%1;MTNM-;- :>-;:Z>X,D$0#9
M3C=_-DY' ]R[G0M_H:39?17BIBAH*.*$N+&?1: 2."S6S-;.[!YJN0OF:^;?
M;W<+G)!I*U P,)W7._..>WD#N[HQ\>:V&B-O=8^\LMFKK?T)>[=Z:,X+#[6;
MO]Z:9-,OHE%R&T;7%OT38^O5OYV63(@A!P9",=N#WCL[5 D&WC5]1,^KAMD,
ME QV7-:W. .."['=[$C#,D1,OJDG(X*.MJ.T^FT#6T%/4V^:K-6W>!8\-W>)
M';[E'FG=NUROVM+?;J>W10T-5*R/SI-YPR0#_5"C_;WJ6XWK5_05U+T,5 X,
M@=^N,9[N\E:C!-TL8=]T_;1=J$>D])6J\1V^2HDN+6.BB,@:&;S=[B<'L]BZ
M#9MJUFL]*TMW93/IG2[P?$YV]@AQ:>/V=R@>Z:UJ:[9#3OO]B@GCIYHZ:%DO
M#>8&<'#S?8I@V57NACV56ZZ2P06ZC9&\N8T^:P![ASP.?]ZDX=B8V2$."JOF
M;46WV\UMVEI](VYIIF$[KG#?=( ?I8P,9X=ZWFS?;N+E=6VO55,RCF>X1LJ
M[ WLXP1CAXIIE-,I]R$RHSVW:\KM"VF@J;=#%,^HE<QP><8QCV'O45UVWO4E
M=0L?9+2UO01YJIC^<:#D]FZ,#"D89DB)E]09"942;$]JCM;BHH;E3L@N4&'9
M:[+9&XY@8&.1[URFT+;9=J?5%39=(T39G4SMUTA\\O(&3AN.&/?V)IGT5/I]
M#9"*)MB>TNNUJ^KH[I;G0U5,"73,^@<$#!&.!X]ZEAO:DQ7LF*51$401$0$1
M$!$1 1$0$1$!$1!0\ERFT?6E+H:R1W.MIIJB-\PA#(B 0<..>/N76=BAGY5/
M^;ZF_P!=;_P/5PQ<TL1<L"G^4=I][PV:U7%C>\;A_O4M:3U+;-4VQM?9J@30
MYP>(RTXS@X)P>*^7M.P[/';+GNO3X1J'=?NACOSF]CS>"V_R;KA6VK3^L:^%
MN]#30ME /!I>&O./W+<X8:G##ZD&!E5R%\NQ;>M3W"G=26NTQR7$O<0YGG@-
MX?U=WV'M4JZKVD#1>CJ&KOT;9;W41Y%*P[F22<'D<# [EG3+-2DW(1?+@VT:
M\DA=<X[,/R6#S$66@9_6PI?V3;3*'7E)(QL?5KE"W>EI]_>X9QO X'#EXI.&
M8)B82)D(HKVM;7*+1+^H4D(K;L><8DW1%PX$\#WC@HI;MSUM"P5M3;(C1'CG
MH]T$?VL)&&9(PS+Z?N55U*@FJ=S?$3=[=SC*C/9IM>BUI4W2+\E24C:&#IG.
MZ4/+@,\ ,#N6PTIKNCUYHBXUM+"Z":%FY-$X[VZXCL.!GD>Q0[\E<ANHK^3@
M@4P.#R/%R1AV6(VE)&S3;,S6.K);,^TOI6EKG12=+O\ T>>1@84P#A[E\Y;!
M[_1W':'<(::Q4=#*8W%TL1&>&>7 +WJ7;K=+%K2NMLMOBFHZ=Q9@/W7.)9D?
MU3_6(2<.^Q,;[/HM<CM1UBS0^EI+LZF=5.Z1L+(VNW?..3DGC@8![%!'S]:I
MHKI%-<[7&RWRN#A"1NN+/8[''P4G;3-54-RV.NOD=##6TL_1.,$IR 2>(SCF
M#[$TS'LJO;?;)=>-UY89*\T;J.6)_1O87[X)[P<#]R[G*BG8!=J2KT ^IBH8
M+;!%,_+(R,<#S)P%Q>M=OM0;JZAT;1-J&-<6BH<[>Z3W-W?[TTS,[)5R^BLI
ME?,MEV^7RW7-D&K;6.A=@$M'1N:,\3C=.5/5[U5;;/I:6_5,O^1,CZ0'D7=P
M'M)4F)@F*=!E,KY:JMO6JKC<9GV*V,ZI&<[F.D.[WDX'8L@_*$NT]50006J*
M)SG-CG#I,^<7XR/-[L*Z)73*6MK.TAFS^&CD?;G5HJ';N&R[F[P=[#^JNKT?
M>1J'3=NNPA, K(&3=&7;V[O#.,_:H)^55*9[/8)7##GEKC]K7J7MC_\ FUTW
M_J,7_"%*V2MG8(B*(H5Q.TW:#1:!HZ6>NI)ZEM2\L:(2.&/>NW7S]\K;_F2R
M_P#;._<KABY7#%RV%%\HS3DT[65%MN,+"<;^&$#V_2"E&#4]!7:4EOUK>*FE
M; Z<!I&3N@\#W'(POF&XP[/QLL@>U\/E-N'A$?/WM\XR/=A=7\G\U7S7:N$N
M>J]')T>>7T#G'VY6YPPU,0D?93M09K^ON%+';'T1I&[V\Z7?WN('<,<U)35\
M4;+M=SZ)J[LZ@H365M8.CA;O8W3O YQ@YY*0=*[>KS!J!E)JRBC;3O.Z[=&X
MZ,GD<8X]W8I."82</#Z81<MKW65OT=IYUTKSOL)#8XVG!D)R0!S[E  V\ZOK
M*J2HM]JB-''Q=&T;Y:/:['L[EF,,RD1,OJA,KYOM>WVY7?5EKHJ2VQ0TE5/%
M"X.DWG-WGX/'='>N[VS;3WZ(IZ2EM].V>Z5;-]@<[ 8,XSC!SR/=R5TS=&F4
MJY1?.F@]M.HJG4]):=06@R=:.&]$W=>T8)SNXXC^Y2?M1VBT&A+6V2=O6*^8
M#H:8.W2[)/$G!P!@]BDQ,;%2[Q,KY;&VC7KX#<F69OY,!^ET7FXS^MA3%LFV
MET.O:*1K8^K7*!@=-3E^]PSC>!P,C[.U)PS!.&4A+G];ZHHM(V&>ZW$N,<0X
M1M(#GGL SVKH%I=3::M.I(8H;U1Q5<<1)8V09 )Q_@%$1MI7;O:-0WZCM=/:
MZV.2I>&![RW )..]3",X7Q]9:&FMOR@FT=#$V&FAK]V.-O)HWAP"^PQV+6*(
MCTLQ0B(LH(B("%$*#F=H&K*?1FGI+M64\M1$UX9N1XSD^]1?#\I"P.>ULMIN
M+&=I&X?[UO\ Y3/^;.H_[9G[U"F@H=!/V>7%VIGP"\@2="-X=)]'S<?:MX<,
M3%RW$15OIO2^L[3J>Q272TS&2*)A=)&<;[".." 2N$V>;9V:MUM+8G6E].UW
M2=#-TV]G=[Q@8R,]I7 ?):,K;WJ,P@FB$.?.' \>&?;C"S]D-_IJW:=>Z>@L
M-%25C8JAPG81EQ:\#'(<TTU:5[?2 "]*$=FNUNXWG753IW45+%2RLWXV%KN<
MC7AN,8[>)^Q;_;;M&ET);Z#J$<<UPJY2 QSL88T<3R/:6K-3Z2I2?D)E<!;-
M<&W;.J74>KFMI7RLWNC:>))&0T>W@5#5PV^:GKZV5]CM<;:.,_1(Z0X[R<#"
M1AF2(F7U)E1YM2VFT^@)*1M3;Y:SK R"QX;CG[/8M#LEVRTNK:@6R\0MH;IG
M$?G[S9>'9P&#[.*B+Y1U_K[GK"6WU=*(J6B+&P2?K@LR>SO<?!:PX=ZE8P[U
M+ZOL-Q;=K125[&&-E1&) TG)&5GY"AO8]KNI=H&MK=0T_5*.UMW&//#?: W'
M9VDK@[KM[U'<;M,W35L8*5KB6M(Z1SF#M/ 8SS^U33-IIE]0+AMJNO6Z!M5/
M7/H'5HEDW-T2;F/MP5"]=\HF[MIJ:.&TQ15; 6U&_)D%V>8&[P[>"Z'Y2U2Z
MMV=V2I> 'S/8\@<LD95C!O4K&'?=,6AM0#4^FJ*[-@-.*F-K^C+M[=R >>!W
MK?+@]AG^;*R?]@S_ (0N\6921$11!$1 1$0$0\EAW:I;1VNLJGG#887R$^P
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M)]B](@H!XJ@7I$'G'%%Z1!XPJX]G%>D4'D #/! %Z1 5"JHJ/..!51V^Q51
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M>\6L'(9))^)*V"B"(B B(@(B("ML_2N]RN*VS],[W(+@[45./8JH"(F4!$1
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M&DJJ6KMS)IJQXP9ZAS7/Q]@"LK*/:35E%I7:IK-]1%-4U=2Z)E/2P#,DSN/
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MFC9&[0H-2=;&Y%1FEZ#<X\=SCG_8^*[+L3*J%$<?HW2+[!?M1W!U6)A=JGK
M8&8Z/SG'&>WZ7P77XXJN40<CIW2;[3K*_7QU4)&W,L(BW,%F[GM[>:NZ\TN_
M4]/;XF5(I^JU<5226;V]N2-?C[=W'VKJ%5"V-+3E] ZGS]*/<S]F%SNS?2K]
M(V*2WR5+:ESJB6??#-WZ;R[&,]F5U:#VH"XC7^@V:EGI+A0ULMLO-&XF&KA
MXC]5P/,<!X+MU3]R"+:C1FKM00BAU)J.-MLY2MHH3&^8=H)<YP'AVK=:%T#!
MI_155IRNE;7TT\CRXEF[EKF@8^"[CD4X<U;6T46_0FK=-"2CTSJ.-]L<3T<5
M;"7NASV AS>' =BN6#9;44&LJ'4M=>YJ^X1M<)S(P>?EI: WN !'?VJ4QE E
MEN,U%HU]UUY8]0BK$;+:TM,.YG?R'CGGA]/X*[M T33ZMIJ9XJ9:*Y4CNDIJ
MJ'&\QWMR.(77A442T6OTCK>Y4HMMVU/''0##734T!;-(![2X@9[>"WVR_0[=
M#V^X4<55UB&>I=-'EN"QI)PT]YQVKLP.:J."MK:S6TT592S4]5&V6"5I8]CA
MD.!X$*+J'06I]+/DIM(7]GY*><LIZV+I.A/;@M<U2N3P5.]1$34&R>L9JZTZ
MCN5^EK;E32E\SI(^#QC :T?U0/MYKK-4Z2?>]5:=N[:H1-M4CY'1[F>DWFEN
M <\.:Z["#V):V8X*-=JF@KSK=\$$%[CH;;$0_H.A+B]XSQ<=[B.)X*2R0J)$
MI&R*Z;1>NJ:&.*#6%/'#& UK&T9  '9]);C6VA9M0T=KJ8+D^COUNRZ*LC:/
M.) R'#N):WM[%WB):VBMNA-1:BN5%-K:[Q2T-&\/;1TL6XV8@YR_+G9Y#EA9
M.U#0%WUG)2P4UZBH+93M'^3B$NZ0YSYQWN(P!P]ZDOOSR3..05LM%5+HG75+
M!'!3:PIXX8P&M8VC(  [/I*2Z6D#::)M4(Y9PP!\A8/./>LM%+1QFH=&-NNL
M+#>HYXX66TOWH>BSTF\".?9S79!N!@8 '+"KPY(@#@B(@(B("(B B(@(B("(
MB"BLR54$4@CDFB8\\FN< 2K^%\T[=JB>+;#IAD<\S&%\.6L>0#^=[E8BUB+?
M24DK(F%\KVL8/ZSC@!>8)HYF;T,C)&'M8X$*)?E'W-]OV6LCAF?')530Q!S'
M8/:[_P"U<Y\E74KZFEN5CJIGRRQDU$1>[)W<@$<>/-P5T[65M:?)JF&G ,\T
M<0/+?<!GQ5QKVEN\' M/'.5\K_*>U3)4ZLI;325$L;*!I<_HW[N7.#>[NP5-
M6SNXNN.R.W5#GN,G4@USB[)) [TG#-1)6UNV%PHR<"KIR>S\XU7C+&(R]TC0
MSZ1<3PQ[U\7;/M(7?6S[NZCOIHGT3@?ST[P'9WNT>Y=KL?K[UJ.UZGT357%[
MWOC+(*E[R[HG%K@>//'FA6<%+.%]*_E&BX_Y93_[UO\ BK]/-%.W>@E9(WEE
MC@0OB?5FD;KIS7%)IJ:\2S35'1XF;(_=&^<+ZBV0Z/K=%Z>FH+A<!6RR3F42
M9)P" ,<?<I.&DF*=VK%3404T?25,L<3/UGN#1\5>RH(VNZ.UCK35S*:FF%)I
M^(@-D,A:WZ(RX@#CQSXK,;D)MHZ^DK0XT=5!/N\^C>'?N5^22.)A=*]K&#FY
MQP OD.V4M=LYVK6^W6B\&Y1O(Z1L+B6N!SYI'+/!?0VU325TUA:8;?;;J+=#
MO%\SN.\_E@ C[5J<-31,4[&&JIYW%L$\4A''#'@E9'+'!?+OR:34Q;0[I35%
M5+-T4&[Y\A(//C@KZ;JZJ&CI)JBID;'#$TO>]QP  ,DJ3%;$Q3Q6W"DH0WKE
M5# '<ND>&Y\5?@E9-&V6%[7QO&6N:<@A?%.V76E1K'4U1/$9&VRD<8:<9X''
M,\.\Y^Q?5VRDYV>V DY/56JSAJ+)BH=8K=1^B*N*W4?HBLH]1_17H\EYC^BJ
MR/:QCGO.&M&23V(+<LL4#"^9[8V#B7.. %A1WJV32='%<:1TGZHF:3^]0U24
MURVP:AK:B>MGH=+6Z8TS:>)Q:ZI(XDDMQPXM'-=76;&-*241BI*>II:@#S*B
M.HDWFGO^EQ5V6DD[PQO9X'BL87*BR0*RFWN[I1_BN-T;9+_I_35WH+[<H[A%
M$V3JLV3TFX6YP[(YYSVE<!LKV<675&D1<[FZM=625,[7/;5RMX-E<!P#@.0"
M44GB.6.1N]&YKV][3E>RX-&20!VDJ"]0Z8O6S%[=0:<NU566F)X%50SO<_$?
M>TN+NWW<U+E'/2ZITQ!/&Z04E? V0%KBUP:X9QD'(^Q0ILH*F"H!Z":*7'/H
MWAV%=D>R-KG2.#&M&27' "B#8Y;(++KO6UMHW3=4IWP"-LDKGXXS#F23V!5V
MTSU5SU5I;2\=;)0T-QD>:E[7%ID:'1C=!''B'$<^U6BDITMTH:R0QTM93S/'
M]5D@<?@5F=G'DH+VF:&MFA[%#J+2TLUOKJ&9CB.F>X3C/%I!)'%33::DU=LI
MJAX+721AQ![R%!<EJZ>&>*&6>-DTO!C"X N]P[5=DD9&PND>QC1S+C@*)+?(
MW5.VJNK7._R'3</1M<3YID<P;WAO'P6I?#==K6J[E%UZ>WZ6M<YA:(G%KJAX
M\T\6XX9#NU**3''>K7))N,N-(YW+=$S<_O6P!\W/@HUJ=C.DWT1BIZ:HIY@!
MB9E1)O@]^=Y;39S8;_IVBKJ"]W-EQHXW8HY23T@9Q&'9'/&.TI0ZS\I4()'6
MZ?/_ &K?\5?CECE;F-['CGEIR/@H V3[/;/JS3U37W=U:^KZT]F^VKE: !C'
M . 6=J72-YV;M.H]*W6KJK?3X?56^HD<_,;>+L%Q=V ]RM%)S<YK6DN(#0,D
MDXPL*&[VZ:<PPUU*^4'&XV5I/AE1MK6YW36.F].4NG6SQ4E[>&U=3$>,$>1O
M<>?+>'!8>K]D]CMFDYZVU23T5SHHNE;6"=^7.'$Y\[CGB./>E%)B>YK&ESG
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M[Y:F0OD)R<]GN6;J"N=<;M/*22UKBQN>X%:X+3\U^;^5.;CF(G:!$11X1$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MKF5+1(1&),OYCO\ H_!*6DW9558I*B*JIXYZ=X?%(-YKAVA7T01$0$1$!$1
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MGG+3AGL\WV\UTMYL-?/M;LEWBAWJ"GHG122=SLR</^\$L2!'&V-@8P!K1P
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M>>PUDIW8GS<8Y'$X #AD9S[5:6DG@( @((X=J\MDC+]W?87=P/%1'I %7DO
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M$0$1$!$1 1$0$1$!$1 1$0$1$!#R*(>106A^F/N5U6A^F/N5U 1$0$1$!$1
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M'7>EB\$Z.N]+%X(/%=9+97RB2OMM%52#DZ:!KR/M(6;!!'!$V."-D<;> 8P
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M B(@(B("(B"W_P#M!]RN#DK8_I!]RN#D@(B("(B B(@(B("(B B(@(B("(B
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MV1$1!$1 1$0$1$!6YOI,]ZN*W-])GO07 B!$!$1 1$0$1$!$1 1$0$1$!$1
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M);[26I]06W6(TKK005-341&:DK*?@Q[1D$$$#CR[^:44E <D5,\%4'*B"(B
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M['-/QU$3ZJ>Y5L$;@YE/4U<CXP0<_1)P5(T$T<\8DAD:]AX@M.05CU]SHJ
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M[$'LK77N]4%EI'U-SJHZ>)O:]P&?<M)M&UG1Z,L3ZR?=EJ7N#(8-[!>XY^
M/@ODW5.H;EJFYNKKO.7OR3'$"=V,'L&?L7L_%_#Q9^_J#TG.^;?[73S.CM%K
MJ:S!QOOD$;3[L;RT#OE!UY)W; P#_6__ "*% ,*J^IA_3\F(WAG5*:?^4%<?
M4,?[5_Y$_P"4%</4,?[3_P"10LBUV.3P:I33_P H*X>H8_VG_P B?\H*X>H8
M_P!I_P#(H61.QR>#5*:?^4%</4,?[3_Y$_Y05P]0Q_M/_D4+(G8Y/!JE-/\
MR@KAZAC_ &G_ ,B?\H*X>H8_VG_R*%D3L<G@U2FG_E!7#U#'^T_^1/\ E!7#
MU#'^T_\ D4+(G8Y/!JE-/_*"N'J&/]I_\B?\H*X>H8_VG_R*%D3L<G@U2FG_
M )05P]0Q_M/_ )$_Y05P]0Q_M/\ Y%"R)V.3P:I33_R@KAZAC_:?_(G_ "@K
MAZAC_:?_ "*%D3L<G@U2FG_E!7#U#'^T_P#D3_E!7#U#'^T_^10LB=CD\&J4
MT_\ *"N'J&/]I_\ (G_*"N'J&/\ :?\ R*%D3L<G@U2FG_E!7#U#'^T_^14;
M\H"X G_V#'Q__J?_ "*%T3L<G@U2FMGR@ZX'SM/L(]E7_P"1=)I[;U9JR9D5
MVH*FWN<<=)OM>P>\\%\WIV\5G%^GY,QM%&I]U6RXT=TI6U%!4QU$#N3V'(6:
M.2^*=#ZPN>C;FVIMKM^G<?SU,XG<>.WEVKZTT/J>BU988+C0O&7#$D><F-W:
MTKY/Y/XN+(G^FHW=$BHWDF>*\HJB(@(B("(B B(@(B("(B B(@(B(+8_I!]R
MN#DK8_I!]RN#D@(B("(B B(@(B("(B B(@(B("(B B(@(B("MR?I&>]7%;D_
M2,]Z"XB(@*CE54<@BG6M@NVLMH$5IKQ40Z5IH!-)NY#:B3AYN?\ :/?R6@VC
M:/MV@66K4&D3^3:MM6R"2*-V&U#""=TC_9!4U72X4]KMT]96R-AIX6E[WN.
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MJIV4U>[?DI'$&,.QQ(X9'BNM["I=%H(V(Z@N<FKM0P2V"IBAJZQTL\Y)Q3.
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M/9-6549PW=CP0WOXEF/M4C1MW(VMR3@ <5EEPNW/ALRO/_\ "_\ %8MI:?\
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MB("(B B(@(BH@JKM#&9Z^CA9]*29C!]K@K*[C8UIR34&N*)VYFDHG=/,X\N
M.Z/'"YYV.,&"<4D/K#3T)IK%;X'?2CIXV'WAH6>J, #<!57Y69N;;$1$!$1
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M8T^HY:K8]'?:L[E1+;&S/<.'GE@R?$JT4[4U5. <SQ</],<%>8X. (((/:%
M&SS9]8[_ *8MU7<[W4ON57$V9\;*^0$%S0<;H>.\]BG.RV^.UVRFHH7/='!&
M(VN>XN<0!CB3Q/)28HEG(B(@B(@(B("(B B(@)A$0,*F%5$%,=Z$95404PF/
M:JH@85,*J(*80M5404#<*H&$1 1$0$1$!6ZC]$5<5NH_1%!ZC^BO2\Q_17I!
M3"8[E5$% W"85404P@"JB"FZF%5$%-U5'!$0$1$!$1 1$0$1$!$1 0\BB'D4
M%H?IC[E=5H?IC[E=01+\HRPWV^Z5IV6#II!%+O301.(,C?[\)\G*P7VQ:2G9
M?^EB$D[G0T\KB3&W 'V9()^U2RX9]Z <5;VI;VI54)Y^Q55,<U$09KBQOU#M
MTI:*.XU5N=^37/Z:F>6OX%O#((X<5U-JV95-#<*:J.K[[.V&1LABDJ)"U^#G
M!&_R*P=;::U:-HL&I-*Q4,FY2&G(J7D<R#W'N67::C:>;E2BY4=E;1F1HF,<
MAW@S/''F\\+7PTY[35@MMXVZZKJ;G##4/HVQ.BBF;O#>)=YV#PR,!=[M*T[:
MKKHZ["MI:</AI9)(IRP!T3FM+FN!YC! Y*+F6J]UFV35MPTQ51PW"B$1Z&7(
MCF:=[+21[NX\UT=UMNT36$'Y)NT-!:+3.-RKDIYG/D>P\PW@.8X?:DCEKC7U
M-PV9Z&EK)'2RMN<,?2/.2X-J&@'P 4BWG6=^ME>^DHM(UU?!$UN[41O9NO\
M-!X9/><*WK'0LTVG]-VJPB-L-LJH9'!YQEK9&N)X=O E2' PLA8T\PT#X),H
MA3;A65=YV;V:>KI9K75372)O1O(+HSAX!X%<W26F]U.M*C2NM]776.GD&_3$
M/<(ZMF0 TG>'$@\O85+&UW2]=JBRV^EMG1=+!71U#^D=CS6AP/9[0K^TG1,6
MK+/&(7=!=:0B6DJ6\',> <#//'']R1-0L2Z/3MGHK!:J>VVN!L%) W=8P?\
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ME>7$-#S@9/8NQU54RT>G+E44[MV:*!SV$'D0%:&U':G/WJ+MB6TJ/6=J90W
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M91PBD?YE=8>BH_\ >G_!/F5UAZ*C_P!Z?\$[O)_D:91PBD?YE=8>BH_]Z?\
M!/F5UAZ*C_WI_P $[O)_D:91PJ*2/F5UAZ*C_P!Z?\$&Q;6!)_-47#_YI_"G
M=Y/\C3*.$*DF/8IJ]S@',HFCO,I_"NIT]L"F>]K[_<PUH.3%3MSD?VOY+.+\
MW)PQ[-,H@TY8;CJ.YQ4-J@=)(\X<_'FL':25]9[-=%TFC;%'31-8ZLD =43
M<7N_P'+[%L]*Z6M6F*$4MHI(X6YRY^Z-YQ]I XK>87R/ROS)S]H]-1%*CM3'
M% B\0(B("(B B(@(B("(B B(@(B("(B"V/Z0?<K@Y*V/Z0?<K@Y("(B B(@(
MB("(B B(@(B("(B B(@(B("(B K<GZ1GO5Q6Y/TC/>@N%<1MAM=UO&@+I26*
M21M:]F0UCBTO .2T$=X!'VKMSR7G"1-" ?DUZ5U+9:ZYU%YCJ*2B> T0RO)W
MW#.78Y=H\%/PY%"$PEVLS:#]KEOJKKM9TO26^X2VZIDB.[4Q#SF?2XA;ZGV3
MU%;50OU3JBY7JEB>'BEF<X1N<.T@.XK:ZDTK<+AM-T_?(#'U*B86R[SO._K<
MA]J[X+5EH2UE9:*X[;],4=33Q/I(J>1XA<P%GFB/ QRPMCM@A9<-4Z.TY.>A
MM%?-*ZI8WS6R[ICPTX_M%=!<]+W"IVJVN_Q]'U"GIY(GY=YV7;F.&/\ 1*SM
MH^CFZMM<3(:AU)<J1_2TE2P<8W\/M&<#EW*66W/Y M)MAMYMM&:(MW.AZ%N[
MNXQRPH2M%94Z5LFT*SV6:1U%;]Y]*YI)Z$OB;D-/9CG]JZCIMJW530=2M D(
MZ/KHF=P'+>QN\^WFMUIK2-OT=HFZ0WJ<U@J6RS5]1(W)>"W!YYX!K4@7]E&F
MK3:M'T,E)34\D]0TRS5)8"^1Q)SEW,]W/L7%;1]/VNW;5M&W"@IX*>JJJEPF
M;&T-W_S;O.(';P'%7-+T&K+5:X_(*Y4-XT]*7.I^N.<UT>3Q:.? '/BM%=+7
M>';6=(R:@N3:J\22OD=2PYZ*FC#'<LGV#L'-6%AN]G-FHJO;)K:X55/'-/!*
M(XS(W>W<AI)'MX+5:SDN5QVU&GAM$5X@MU'O0T,[\1@DCSP,$?#M4BZ'TO7V
MC66J;G5]'U>XSA\.Z[)P !Q\%9U[HVY5-\IM3:4J(X+[3L,);+PCFC/8XCW#
MO4LMRVJFZFU#9:BAN.A+>8W,+6R.E&8CC&\T[O#'L5Q^C]1WO9=98*N>*2]6
MR<5#!.[I&3;O$!QP<Y/>"LJY4VTO4].;950V^S4<HW)ZB&9SY-T\#NC P?M7
M1WJRZALFF[71Z)FAE?1'$C*QQ_/-[M[L/V=J6-5HO4EMU-<*RWW6R-LVIQ"8
MWA\30]S"'<6/'$C&]W+F[;/)H"?\@:OL<%;8)ZG>AN+8FO8PN=PZ0. / XX\
M5O;!I75%SU74:HU%U2AN$=*ZGHHH"9 PEKAO.) _6^"P+O9-H>I*(Z=O45L;
M;)I6BHKF/)>Z,/#N#<<^'>@EZE=$^FA=3[O0E@,>Z,#=QPQ[,*+9,#Y1<6>9
MM3L>WZ*D^V48H+;2TC"7-@B;$">W Q_<N%VBZ0NE9>J#4NE9XXKY1-Z(1RDB
M.:,Y!#B/?\$A(9>VIP&S>[YX98!@^]1[M(MD%UMVS"WU[@RGFE8R0DXX;@X+
M;W.Q:]UL^FH-1LH;59V2-DG%-*7OEQV<AP.?@%:V[6CKUPT-:Z69U+OUIBCD
M9SC\W@1R5CA82M3V*U06T4$5MHVT0&Z(1"W<Q[L841Z3D?I.^Z^MED<Y]!30
MMJX(6G+8)#TH+0.SZ#?!;GK&U*EINHQT5IJ7M\UM<^9PS_I%N[_>N@V=:(&F
M[?<'7&H-=<[F\25DSQG>./H\>8&7>*GI/32;#-/VQNE(KT^**JNM>]TU14R-
MWY,G'F[QXX&.7M6EV\:<M4-18+S!3P4]P_*-/&YS&[IE;T@YXYXSV]RS*/2V
ML="UU2S1[J:YV6HD,HI:J0L="X\PW (Q@#N[5K]1Z(UMJZIMMSO<]) ^DJXI
M&6^*0F-K&O!+B<<78SV=RL>U^;7M4TL6H=M5EM%W=OVNFHFU3*60YCED\[CC
MD?Y*3KYIZTW&R3T-7;Z5U+T9 9T3<,X<".'#'L7-;0="U%ZJ:"]62I%)J"W-
M'0R<FR 9\UQ''!WBM1,-IUXI/R;54MLMT<@Z.:LBF<YV[VEHW1@_:HBSL%H8
M*2Q:@H8\24]/7S1LWN.6MDD Y^Y6MAQ%-H.\5,,33-'7S[I#1GZ7)=#LDT?7
M:1LUQH:Z5LSI*B1T<N<N>TO<0YWM((*R-DVEZW3.GZRBNHB+YJR6<!AR-UQR
M%;$3[(':@I[*^[46EJ:ZUE:\RRU\TWYQ^<''$'',G[5N+G;-4U^L+%=X--TE
MEJX:EG3S0S .GBWAO,=@#>X9\5NZ'2NKM!UE3'H[JURLM0\R-I*J0QF YY-P
M",8P.0Y+.L>FM5W[4U)>=9U,=)!1.#Z>AHY'%I<"#EQX9Y#L2UM)P)+>(X]J
MBJA_SXWDX_\ W>W'@5*P!"X6ETQ7Q[3+C?'=%U*>E$3./G;PSV8]JD)#D-A&
MG*"2XZEO5130S5IN,T<<CV!QC;OG(&>7);/55)!;]M>E*NDC9#+5Q2PSN8-W
MI!NN(WL<_HCP70[+M-UVFZ2[1W#HR^JK9:AFX[(W7.)'9[4U-INMN.OM-7B#
MH^J4'2=+O'SN+7@8^\%?DO=VX7.;1?\ H->Q_P#TK_W+HQR6GU?;YKKIFYT-
M-N]/40.C9O' R0LPC0[&?\V6GN[JK?W*.(M-5.H]KVK8Z2^5UH,38B74CW-,
MF3)SP1RQ\5+&SNSU5BT7:;97%IJ::!K'[IR,CN6HTOI>X6W:'J2\U'1]4KVQ
M"$-=Q\TOSG[P5B5MP&TK9Y<+7HNYUD^L;U6QQ,R8)I7EK^/(Y>5*VSYS6:&M
M#GD "G!)/(<UYVCV:JO^CKE;:#=ZS.S=9OG Y]I7):JL6L#H&@L&G.K13F$1
MU,YE<TM&3D-P.W@/M*MW![:[5=XJ]HU]\EM-2.99X'AUSK1]%[1C\VWOX\^7
M(J0;EIRUSZ6BTU*YL% 864[8VOW"YC0, 8(/8HTTI9=H^E[1';[3:[!'&WBY
M_2$.><DY<0SB>)72ZMTMJ'4>F[16.GAH]46]XG;T;CT3G8(+<\#@Y4&GUILJ
MLEKTS45NFWU%IN-)'O15$53(",<,'SEW6S.]3Z@T5:;E69ZS/3L=(>]Q:"3\
M5']YH-I.KK<;+<J:WVFCE&[4U4,SG.</]$8'[U*^GK33V.STENHFX@IHVQ-X
M8R ,)(V*(BB"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B K=1^B
M*N*W4?HB@]1_17I>8_HKT@(B("(B B(@(B("(B B(@(B("(B B(@(B("'D40
M\B@M#],?<KJM#],?<KJ BH>: \5!5$5,G)5%4/(J*-5ZIU1<]</TQHTTD#Z:
M'IJBHJ6EW;@  $+>;.+UJ>JGN%MU?;>AJ:1P#*N-CFQ3CB,MSSY=_:BTW5HT
MK16O4MVO<#I755Q#!*'?1&[G&/%=".2CVBU95S;5ZVPOFI_R9%1,G9W[Q+NW
M/L"V%HBU2W6]QDN%92/T^6CJ\3!Y[>!Y\>]6AV2*Q)5011]))-&R/]9S@!XK
MW',R2,21O8^,C(<TY&%$7,(L>GJX)][H)HY=WF&.!QX*^"@JBCS;'JF[Z9M=
MK=813FJK*QM.#,TEH!!/81W+17&Z[4K#1S7&NIK17TM.TOEBIVN#RT?J^<>*
MM+28$6DT??X-3:>I+K2 M9.P$L=S:>T%;MO)1!$1 1$0$1$!6YOI,]ZN*W-]
M)GO07.Q<OM)O4NGM%72Y4P!FA8T,SV%S@W^]=1V+5:DL\%^LE9;*K]#4,W3C
ML.<@^("#A=F>SRS1:;I;E=Z6&YW2XQ-JIIZJ,/=F0!Q )XXXKCM9Z,HM,;4-
M'5-J)BHZRL=FD  CC>"PY:!P&<E;S3U\U9H6B;9+KIRNO-/3#HZ6KH8GNS&.
M#0X!IXX 6LN5NUGJ37FE[Y<[:::V05),=,&DO@:2W+GG'#@!W=JU#4+=)I6C
MU1MSU(+IF6CI(XI'4QP62NR[&\#S P?%;C:YIVV6!MEU!9J.&AKZ2MB9FG8&
M=(UTC00XCLQGQ6\TE9KA2;5=67&HII&4=3%"(92TX>07YP>WF%D;8[377?35
M/3VZGDGE;60R.:QI)W1(TD\/8"I9;F-6TTFM]I=HL%=*]MFI:-E;40 Y$[BY
M^&N'(C\V/%==?]FVFJ^R/I(K52TDC&YBF@B:U\;AQ!!QWK2:YTU>::]6?5FF
M&-EN%!3MAJ:1P/Y^,9):/]+#G?!6ZK6VJKW1NM]GTC<*&OE;N.J:UCVQ1]YR
M6C/LXHG_ !X^3A"ZFT=<*=\G2/BN$S"\\W8>1DKO=;_]$;O_ *L_]RY+818[
MI8=*55+>X7Q5;JR60[S2-_+B=X9["NRU;3RU>F;G! POFD@<UC0,DDA/D^4,
M:>T;->-E6E[Y89.K7^WP"2*1@QTS<<6.(XXX#P7C7NM(M7;+G":/J]VI:J..
MLI2>,3_.!^S(*D_9#;JNU;.[-17&!\%3# &O8]I!:?M7$[8]EAO55^7; UPN
M.]FH@'$3CL(]O/Q5B=]UB=W;Z_T11ZSM=/'--)25M-Y]-5Q#SXB<<O =HY+F
M=!:PO-NU*-(ZTB:*X,WJ6L:XD5#!PXY[>![>U9NLZW5VGM14UUM=++=[&Z+<
MGH86$RL<#])N >>>[L6AMD-^U[KZUWJNLU39K5:_.8VJC<V61^<\B!PY?%09
M.B0P;==8&K_I(@BZ+>_4W1R^W>4OC*C3:+HZZ37ZEU5I"5D=\IF")\4H\V>,
M$G=]_$K$BVFWZ!@AKM!WPU@&"887N8X]X.YP">T]I5*B;93_ )S-?_ZVW_A"
MVFC'ZTO&H7W:^AEKL^Z1#;]TF0_VR<<>WDN3M]1J326OM5UE-I:ON=-7U ?'
M)$' 8 ';NG*1 [#;[TIV7WCH,YPW>Q^KO+IM#"G&C[)U+'5NIP]'C]7<&%J]
M/W"KUA:KA2Z@T_4VN(X9T<Y/YP'M&6CN7!V6/6.S%TMOCMLNH=/!QZMU9KC-
M"T<@< ]F.SL2O@_I-?\ ZX+TWDHCK-=ZMOL+J/3.DKA05,@W357&)[&1YX9P
M6CESYJ0]'T5RM]BIZ>]5PKJYOTY@W=RI13<HB(@B(@(B("(B B(@(B("(B B
M(@*VS],[W*XK;/TKO<@N#M1!VH@)A$0."<$3 0."<$P$P$#@G!,!,! X)P3
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MT$E)<:8B*JI)1NO8[W'CC(*T53M!K]+:GN5%K"@FBMCWE]#64\#Y&%F3@.W
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M?QQC/?X+2[8J"GMNH-*WBAB;#61U?1%T8QO-=C@?!9=G:UVW*\ C(-!%G/\
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MIBB;>[!-(9F0.D:Q\#G<P,D<,C/VK7:IT]KO6[K?6W&D904])512,M[9&$N
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MM0)'2O\ N._P7#%^5DX9J<4.D96/%O$.D&$7-^6-J'_6O_W;O\$\LK5Z5_\
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M<9.'.QSP$%]%9CJJ>2HD@CGC=/&,OC!XM]ZO=N$!,K%?<*)CG-=64S7#F#(
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MJ*MTOH:XW.V1E]5&T!AQD,R<;Q]V<_8NS/)8U;2P5]++2UD3)J>5I:^-XR'
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M)6W'1U$V[6>N(?/0.=N&)XYEI&>8 [%B:N;KO7EDK+>VR"P41B<YP?*9))W
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MU+IB9Y= TS;KH3G. 1D'GCD.2YS;%%J^\Z6-7J:.GM-+'(UM/00.,CIWN/\
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M("(B B(@(B("(B B(@(B("(B B(@(B("MR?I&>]7%;D_2,]Z"XB(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M@IW/E]-]5'W_ .2>7TWU4??_ )+ANWBG).AE\%.Y\OIOJH^__)/+Z;ZJ/O\
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M^_\ R7#(G0R^"G<^7TWU8??_ )*AU[*>=,W[_P#)<.B=#+X*=SY?3?56_?\
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MT,O@IW/E]-]5'W_Y)Y?3?51]_P#DN&1.AE\%.Y\OIOJH^_\ R3R^F^JC[_\
M)<,B=#+X*=SY?3?51]_^2>7TWU4??_DN&1.AE\%.Y\OIOJH^_P#R3R^F^JC[
M_P#)<,B=#+X*=SY?3?51]_\ DGE]-]5'W_Y+AD3H9?!3N?+Z;ZJ/O_R3R^F^
MJC[_ /)<,B=#+X*=SY?3?51]_P#DGE]-]5'W_P"2X9$Z&7P4[GR^F^JC[_\
M)/+Z;ZJ/O_R7#(G0R^"G<^7TWU4??_DGE]-]5'W_ .2X9$Z&7P4[GR^F^JC[
M_P#)4&O91DBE;Q_T_P"2X=$Z&7P4[GR^F^JC[_\ )/+Z;ZJ/O_R7#(G0R^"G
M<^7TWU4??_DGE]-]5'W_ .2X9$Z&7P4[GR^F^JC[_P#)/+Z;ZJ/O_P EPR)T
M,O@IW/E]-]5'W_Y)Y?3?51]_^2X9$Z&7P4[GR^F^JC[_ /)/+Z;ZJ/O_ ,EP
MR)T,O@IW/E]-]5'W_P"2>7TWU4??_DN&1.AE\%.Y\OIOJH^__)/+Z;ZJ/O\
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M@*W-])GO5Q6YOI,]Z"X$0(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M::?SKN[""XJ%P:.) '>5HK_J.GM@,;2):C]4=GO7!W'4-PK'NWZA[&'^JPX
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MBMK^I*+5\%DUQ1,B;4'&\&[KF'L...1S4H;5M3W;3EEC.GJ!U;<IW8:W&6M
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M[K+>]+VRYU#&QRU,(D<UO($K==G]Z(]91:ZW7>AN%95TU'4-EGI7!DS1S:2
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M;E:+]1%T0,;:5SQV.#2!_P!UI6X]4L>J<-K]U3K?6FJKI3N/5K>QS\\_,:<
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MD[W%=;=-6NJ8@0T2R CC[ T+A-3[4=1:*VH5E)?VF6P=(XQ 1EI,9P6EI[2
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M4T3&N:R)C6GF T %7D08W4:;ZO#C^P%?:P-:&@8'<.Q>D04 XJJ(@(B("(B
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MN6"RRVYARVCBS[EFPP10C$4;&#N:T!7<(I,S/M#"(B@(B("(B B(@(B("(B
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MB66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4/5]E^/\
M%4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/
M\52:B66C'K.U#>)_)]E^/\55ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5
M]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4
M/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M
M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5
M.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/
M\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X
M_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7Q/\ %5'5.U X_P#9]EX>T_Q5)R)9
M:,A5[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHE
MEHRZWM0]7V7X_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5
M)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%
M4FHEEHRZWM0]7V7X_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7
MX_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9
M?C_%4FHEEHRZWM0]7V7X_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0
M]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U
M#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4
MZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_%
M3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4/5]E^/\ %4FHEEHRZWM0]7V7
MX_Q505.U .)_)]EX^_\ BJ3D2RT9=;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&76
M]J'J^R_'^*G6]J'J^R_'^*I-1++1EUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT9=
M;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&76]J'J^R_'^*G6]J'J^R_'^*I-1++1E
MUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT9=;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&
M76]J'J^R_'^*G6]J'J^R_'^*I-1++1EUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT
M9=;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&76]J'J^R_'^*G6]J'J^R_'^*I-1++
M1EUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT9=;VH>K[+\?XJH*G:@"?_ &?9>/M/
M\52<B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4/5]E
M^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5
M]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5.M[4
M/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M
M[4/5]E^/\52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_P 5
M.M[4/5]E^/\ %4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)9:,>M;4-[/Y/L
MOQ_BJO6]J'J^R_'^*I-1+$9=;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&76]J'J^
MR_'^*G6]J'J^R_'^*I-1++1EUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT9=;VH>K
M[+\?XJ=;VH>K[+\?XJDU$LM&76]J'J^R_'^*G6]J'J^R_'^*I-1++1EUO:AZ
MOLOQ_BIUO:AZOLOQ_BJ342RT9=;VH>K[+\?XJ=;VH>K[+\?XJDU$LM&76]J'
MJ^R_'^*G6]J'J^R_'^*I-1++1EUO:AZOLOQ_BIUO:AZOLOQ_BJ342RT9=;VH
M>K[+\?XJ=;VH>K[+\?XJDU$LM&76]J'J^R_'^*J&IVH'!_)]EX>T_P 52<B6
M6C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q5)J)
M9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_ !4ZWM0]7V7X_P 5
M2:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_Q4ZWM0]7V7X_Q
M5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_ !4ZWM0]7V7X
M_P 52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_Q4ZWM0]7V
M7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_ !4ZWM0]
M7V7X_P 52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_Q4ZWM
M0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_ !4Z
MWM0]7V7X_P 52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V7X_Q
M4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?9?C_
M !4ZWM0]7V7X_P 52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEEHRZWM0]7V
M7X_Q4ZWM0]7V7X_Q5)J)9:,NM[4/5]E^/\5.M[4/5]E^/\52:B66C+K>U#U?
M9?C_ !4ZWM0]7V7X_P 52:B66C+K>U#U?9?C_%3K>U#U?9?C_%4FHEHC+K>U
M#U?9?C_%5HMVFU=91B=ENHZ9DF]*8/I.;@\.+SVD>"E)$M;>0"B](LH'DL&K
MNE)22LCJ*B-CWN#0">TE9QY%<1J_1LE\N452VI;&,M!&[@X!XY(^E[CP5@=9
M^4*;K,5.)V&65N]&T?UAQX_ JY!4Q3[_ $,C7[CMUV.P]RXV2G%!K&Q0N<TB
M&E>"X-W0<!_8M=HVLFMU\EDJ9'.HKO/(8LG@Q["X?$,^*M"1)*F*.6.)\C1)
M(<,:>9X$_P!Q6NKM16RAJG4U55-9.T ENZ3@'W!<5<:Z:NU?1W6*5PMU)4FD
M:W]9QC=EWV'(5^HJ'P:VO CM#KB71QYPUIW?-;SRE#KYM16N&DCJ7U;##(<-
M< 2,_9R5RU7N@NKGB@J!-N $[H../+FN7L]DEI++>9ZZF@A%272QTS1EL(\[
MARP#Q[.Y9>C:BAM>B[54U!CIP^%C2_=XDX]B#J*NJAHZ:2HJ9!'#&TN<X]@6
M#;K];[C/T-'4"23&<;I'#[1[%K-1?_J3353!9)H972.Z,E^0W':#P[BL>P5\
MM'>8K1=*"G@JGQ;\,U/Q:]H!R#D @\.[M4'0PW>BFN,E!'4-=5QMWG1X.<+-
M+L DG _<N0DC9'M-B+&,:74&20,9.\\+UK6\/#V66WSMBKZD9=(2 (H^))/M
M(!'VA6(L=/25<56QSZ>1LC6N+"1RR"01X@K(7(;,VLAT^ZG;,)70SS,+LY+O
MSKN)]_-=>H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B >2I[%4\EKJVYLHZRE@DC>[K#MUKP. .?YH-=
M>K'/6WJ&N@FC8(Z>2'==G.\YK@#XN"QJG2O6-(LM3IFMJH\NCJ&@^8XOWLCM
M]BS;IJFTVNK=35E4V.8#>(Y\.]9MHO%#>(3);JED[1P.Z<X]Z#35.ESY-4MM
MI)&,GAD9*97#@YV<N/O.3XK/MUJEIM05]P=(PLJ&M:&CF, #^Y;G&,\$08]P
M@=4T$\#';KI&%H)[,K!L%I%!8:*WU71S.@C#"<9!(]ZVV4[/\4&COEIK)6TT
MEEJ6T<].XNW.(CE!QP=CW=QYK$M5CN$E]%WOD\#IH8^C@BAR6L'')R0.)SW=
MBWMPKH*&-DE2[=8Y[8Q[23@+)'$9'O0:62T2NU;'=A(SH6TW0%F/.SEQS\5Z
MN&FK3<*F2JJJ&&6I>-TR.:">6 MS[!\$P<(-!I'3T5@IIV,;%TLLKW%S!_5+
MB6C[ 0%T*\\DY(/2+R/BG;S^"#TB\_W*A.!RY(/:+$M]=!<(3+2OWXPXL)]H
M.#\0K3+I3NNK[<'.ZRUF^1CACWH-@B\CD.]4<0&DG@.:#VBPK9<*>Y4QFI'[
M\0<69]HYK*/M0>T7E/M0>D7GGW("@](L6NJXJ&DEJ:DD11C+B!G@O5%51UM)
M#4P$F*5H>T^PC(09"+R.+?>@YG*#TBH%3M0>D7D<BM?^5Z/I*Z/I27T>.F':
MW(!'[P@V2+%M]9%<*.&JIBXPRL#VY'81D+([,GD@](M137^WU'5^BEST[G,C
MX<RW&?WA;7]P0>D7E/:@](O/BG>@](O/8J\>/<@JBH/>53M0>D7GM6)^4*;\
MIF@WQUH1]*6?Z.<909J+R#PYH/@@](L2XUL-OHI:JI=N01#><<<E?BD;)$U[
M3EKAD$]R"XBPK7<*>YT;:FD?OQ.S@K+'[D'I%Y&.SBB#TB\^Q![4'I%Y^*>_
M&4'I%Y]B>[P0>D7G]RQZZLAH:62HJ';D,>-YW=DX_O092*S#*V:%DL9WF2-#
MFGO!XA:V._T+[T^UL<]]6SZ8:W(:?:4&X1>>U$'I%Y0>S/O0>D7D\_8L22XT
MT=QCH72#K4C"]K/]$<T&:BPK=<:>X";JLF_T,AB?PY.!(/[EECMX\.Q!Z1>?
M8JCVH*HM#==56FV50IJFI!J,9,;/.(]X639;Y;[RQ[K?4-E+3AS1S;[P@VJ*
MBPJVXT]%/30U#]Q]0_HXQWG!/]Q09R+13:GML5%454DKFQ02F%W#CO@D8 _V
M2MI0U3*RECJ(@X,D&\ X8("#)1>>7#M0=OL0>D7G[,+7VV[4MQGJHJ5Q+J=X
M9)D8XXS_ 'H-DB\^'%"< Y*#TBPZ"N@KX9)*602,8]T;B.QP."%E _!!Z1>>
M.5K)+Y0QP5\KI"6T.>FP,[N!G]R#:HM;'>*-[Z)@EP^M:70@CBX 9*V ]Z#T
MBQJRJBHJ:2>=V[&SZ1[N.%<IY63P1RQG+)&AS3W@\0@NHO/8G(<^'+B@](O(
M[5K;Q>Z.TN@95N?OSNW6-8W>)0;1%9DF9'3NF><1M;ODGL &5S]/K6PSSMB9
M7QASW;HR>!/+"#ID7EIR 0<@C(1!Z1><]N."<^"#TBIS"H/:@](O([?W*G+B
M@]HO/+"(/2*S43,@A?+*<1L!<X^P+7NOM"(Z!_2.<RM(; 0,[V<?XA!MD7D>
M]!W=J#TBIV]JMS2LBB?)([=8T9)]B"ZBM02LGACEB<'1O:'-<.T'B%XCJ8GU
M,D#'@RQ@%S>T9SC]R#(1><_X93W(/2+#N5?3VZG$]6_<C+FLS[2<!6J*ZTU9
M75-' XF:GQO@C@,@$?O0;%%Y6"VZTSKN^V-<>MLCZ4C'#=X=OVA!L$7GQ3G[
MT'I%YRO+WB-CGR'#6C)/<$%Q%K:2[TE3;'7!LFY2#),DG#@.96H&NK"9,=;'
M1YQTF/,S[T'4HL&6YTD;:9SIF[M2=V)V>#C@G]P*U5;K&RT59-35%8ULT3MU
MX/)I0=&BP6W.D=0-K6SQNI7 .$H/ Y69G(R.1[4'I%ABO@='4.8\/%.2V0-X
MD$=BI:;A3W6@CK*1Q?#)G!(X\#C^Y!FHM1=[PVAJ&4\4$E14O;O]&SL;QX_
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MY+9.L5VME95&PS49I*AQD,=3&7%CSS((([<]_-;BQVR:CM[XJ^I-3/*2Z1V
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M>9.3Q^*]&T2'4\ES#V]$ZE;!N=N0YQS_ -Y!IMFE)+3VVIDDK))V.FD:&.'
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MUJADHK34T+J+/YIU1$7/B;V#((!X8[%F5FEWS66EI^N2&NI7]/%4NQ],'(R
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M5U98^JOO=)412[C61TS/S[^(P'#)QCMX#D@WS:ZYWVMIK92U3J...DCGGJ6
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MN?+FLNS:8J*"2T.?.QPHNEWP!]+?+R,??'@LV]626ONL%5'(UK(X)(B"..7
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M" >'L5XZ?N538;G3W"O$]96-W<AN(X_8!S[>\JC22PWNW:=BO1NKB^*,3.I
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MN0HZM-#<[T;S-/>:F%D-9+'3MCP-P!QY]_VJQ2QWBY:2DOE3=YXZR.$RQ-C
M#.#<C( P<^T)0DS(7A[6O8YK@'-(P01D$*.[[J"LK:BVT4#JF%DD)GF=3@%[
MAG&Z.[D>([UYM=QN=)=701&ODMTL3SFI S$X-)!!YD9PE#N[C5LMM!)/T+Y&
M1X&Y$TD\2!P ]ZR::4301R[KF[[0[!'$9':HZI/RFS2%5>*BYU$E2]Q$8.-U
MC>EW>7+DLZGFK]0W9U"VNDI:6DAC,O1<'S.+&G.>8'G=_8E#O <KR>:TMDM=
M;;:N827&6JHG-\R.4 N:[AV\R.?:L'6-PJQ56^UV^;J\M9)AT^ =UO'.,]N<
M*#H)Z*FG<#-!&]P[2WBKL;6L9NL :T<@!@*/]34%SL$5#/0WFJ?%)4,CF9*0
M[>&#R)R1R[%?IX+C>=6WJE?<IX;?3%F(H\ DG>[1Q'+O0=I7U<=!15%5.<10
ML+WGV 96(^\1!U"&132-JOHO:PD-X<SPX+BYW553I74]!65DLKJ!TC62\ YS
M P'!^/BLF*6HM5+IYD55*]DA<YX=Q) 83CX*T.^;S7I<)9*.OU)1NNM1=JB#
MI'O;##"<-C#7%O'O/ GCGFM;!?;K0:9NAGJGU-:VLZO'*&C@#CD,8Y?%*$FH
MHLZS<Z/H)Z*:[2U0<WIA.T;D@)X\#P;]F%M(67*]:MNE.ZX3T]OA9$XPQX#M
MYS<XSS';R*4._P HN6T7/5-J;M;ZRI?4BCF#8Y'@9W3O  _=6'J%M?7ZPI+=
M!<):6E= 7RMCX%W'L/,*#M<A 5&=TN-74Z@JZ'I;@**C:(PVF'G/=S))Y]H[
M5DVJ^7*W6V\]9%3-%2Q])3S5#0UQ)X;IQW'CGVJT)")XJJXJAL=QKK='727N
MI;73L$K2W&XS/$#=Y$=G$+&U9<[C3SVRSMGGZ22/I*B>G8-]P&1@#'#)QR4'
M?#BAY*.K)6W&EOD,,!N$E!,QP>VJ _-NQD.!/'LY9[572UMN=]MTM5<+W5 =
M*]L+8L-W #S.,9[.>5:'>U50RFII9Y/T<;2X\.P+S;ZJ.NHXJF$DQ2C>;D+B
MHYJNOT_>[;7U;WU% 7--0S#>D&#C.,=RPJ&2LBM-@L]#62Q/N <Y\YP3&UN"
M0W/LRE"2F\NQ57#S05VFKO:RRXSU='5S-@EAF()!)#0X'G_6Y>Q>=&T]?<9:
MVNK;G4.$<\D4,8.&M&.&<<^9YJ#NEJ:B_44%16P22D24C6OE&Z> .,=GM"O6
M2BEM]"(*BKEJY YSC))C)RXG'V9PN'O7_/FK/]5B_<Q('<"ZT?\ D>9FM-8
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MPJ6^UBCNE=6"0NZT&#=_5W2[\7P6R[.:J#QYI8YRITP)XKVPU!'Y2]GT.?\
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M7QW"U5AHZT,#'NW0YLK1R#@<CO[.U8]NTS51Z@I[O<;F^KJ(FN9N[H#0"",
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M&P1]8:W(>,<01_-8[-.72LFB-YO!G@C<'"*&/HP2._B4'5C'<%RNT6:KAME
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M 3 0:.FT]1Q6VKH7[TL-3(9';W,$@<O!:Z+1^3%%676MJJ.)P<V!Y &0<C)
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MD!P_P"V>$P$&KMEIBH:ZOJ8WN+ZQP>\.Y C/+Q5(K)217M]UBC#*F2,QR$<
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JB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45765506411408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Nov. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001806952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Lyell Immunopharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45765505068960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Nov. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">37,499,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 35,249,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 5,396.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the $1.88 (high) and $0.98 (low) sales price of the registrant&#8217;s common stock as reported on the Nasdaq Global Select Market on November&#160;22, 2024, which date is within five business days prior to the filing of this registration statement. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Shares of common stock registered for resale pursuant to this registration statement are shares which are to be offered by the selling securityholders named herein. In the event of a stock split, stock dividend or recapitalization involving the common stock, the number of shares registered shall automatically be adjusted to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act of&#160;1933, as amended. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45765505049280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Nov. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 35,249,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">5,396.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 5,396.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-;100.7O-K#*J-]N9 [R6.8XAM#1)U6".((3O7W3'7KO+)B]!K-G<X^FP)3
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M4$L! A0#%     @ 3H)]65*,UH3O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3H)]69E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !.@GU913=-2$@"   U!@  &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3H)]64U3=-;"!   H P
M !@              ("!C H  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+
M 0(4 Q0    ( $Z"?5E>+38E/P(  -0%   8              " @80/  !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !.@GU9*R M?A8#
M   6$0  #0              @ 'Y$0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( $Z"?5F7BKL<P    !,"   +              "  3H5  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( $Z"?5E2<6^U70$  $@#   /              "
M 2,6  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !.@GU9NVSJ[+H    :
M P  &@              @ &M%P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !.@GU9IOQ*6R,!  #?!   $P              @ &?
L&   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "P + ,H"  #S&0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d907660dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d907660dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d907660dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d907660dexfilingfees.htm">d907660dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/ffd/2024q2</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d907660dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d907660dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 1,
    "http://xbrl.sec.gov/ffd/2024q2": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2024q2": 18,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P11_29_2024To11_29_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P11_29_2024To11_29_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "P11_29_2024To11_29_2024",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P11_29_2024To11_29_2024",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d907660dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee prevoiusly paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-268106-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-268106-xbrl.zip
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B;&EN9V9E97,N:'1M4$L%!@     !  $ 1@   (H.      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d907660dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
      xlink:type="simple"/>
    <context id="P11_29_2024To11_29_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
        </entity>
        <period>
            <startDate>2024-11-29</startDate>
            <endDate>2024-11-29</endDate>
        </period>
    </context>
    <context id="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806952</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-29</startDate>
            <endDate>2024-11-29</endDate>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="P11_29_2024To11_29_2024" id="ixv-431">0001806952</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="P11_29_2024To11_29_2024" id="ixv-432">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:OfferingSctyTitl
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      id="hidden126672726">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:FormTp contextRef="P11_29_2024To11_29_2024" id="ixv-458">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="P11_29_2024To11_29_2024" id="ixv-459">S-3</ffd:SubmissnTp>
    <dei:EntityRegistrantName contextRef="P11_29_2024To11_29_2024" id="ixv-460">Lyell Immunopharma, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      id="ixv-461">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      id="ixv-462">Equity</ffd:OfferingSctyTp>
    <ffd:FeesOthrRuleFlg
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      id="ixv-463">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      decimals="0"
      id="ixv-464"
      unitRef="Unit_shares">37499981</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      decimals="2"
      id="ixv-465"
      unitRef="Unit_pure">0.94</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      decimals="0"
      id="ixv-466"
      unitRef="Unit_USD">35249982</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      decimals="INF"
      id="ixv-467"
      unitRef="Unit_pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      decimals="2"
      id="ixv-468"
      unitRef="Unit_USD">5396.77</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="P11_29_2024To11_29_2024"
      decimals="0"
      id="ixv-469"
      unitRef="Unit_USD">35249982</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="P11_29_2024To11_29_2024"
      decimals="2"
      id="ixv-470"
      unitRef="Unit_USD">5396.77</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="P11_29_2024To11_29_2024"
      decimals="0"
      id="ixv-471"
      unitRef="Unit_USD">0</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt
      contextRef="P11_29_2024To11_29_2024"
      decimals="0"
      id="ixv-472"
      unitRef="Unit_USD">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="P11_29_2024To11_29_2024"
      decimals="2"
      id="ixv-473"
      unitRef="Unit_USD">5396.77</ffd:NetFeeAmt>
    <ffd:OfferingNote
      contextRef="P11_29_2024To11_29_2024_1TypedMemberffdOfferingAxis"
      id="ixv-416">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee. The proposed maximum offering price per unit and the maximum aggregate offering price are based on the average of the $1.88 (high) and $0.98 (low) sales price of the registrant&#x2019;s common stock as reported on the Nasdaq Global Select Market on November&#160;22, 2024, which date is within five business days prior to the filing of this registration statement. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Shares of common stock registered for resale pursuant to this registration statement are shares which are to be offered by the selling securityholders named herein. In the event of a stock split, stock dividend or recapitalization involving the common stock, the number of shares registered shall automatically be adjusted to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act of&#160;1933, as amended. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
